ENGINEERED NANOPARTICLES FOR DETECTION AND TREATMENT OF BACTERIA AND BIOFILMS by Li, Xiaoning
University of Massachusetts Amherst 
ScholarWorks@UMass Amherst 
Doctoral Dissertations Dissertations and Theses 
Fall November 2014 
ENGINEERED NANOPARTICLES FOR DETECTION AND 
TREATMENT OF BACTERIA AND BIOFILMS 
Xiaoning Li 
Follow this and additional works at: https://scholarworks.umass.edu/dissertations_2 
 Part of the Other Chemistry Commons 
Recommended Citation 
Li, Xiaoning, "ENGINEERED NANOPARTICLES FOR DETECTION AND TREATMENT OF BACTERIA AND 
BIOFILMS" (2014). Doctoral Dissertations. 272. 
https://doi.org/10.7275/ffxa-6t83 https://scholarworks.umass.edu/dissertations_2/272 
This Open Access Dissertation is brought to you for free and open access by the Dissertations and Theses at 
ScholarWorks@UMass Amherst. It has been accepted for inclusion in Doctoral Dissertations by an authorized 
administrator of ScholarWorks@UMass Amherst. For more information, please contact 
scholarworks@library.umass.edu. 
  
 
ENGINEERED NANOPARTICLES FOR DETECTION AND TREATMENT 
OF BACTERIA AND BIOFILMS 
 
 
 
A Dissertation Presented  
 
By 
XIAONING LI 
 
 
 
 
Submitted to the Graduate School of the  
University of Massachusetts Amherst in partial fulfillment 
of the requirements for the degree of 
DOCTOR OF PHILOSOPHY 
 
September 2014 
                                                                 Chemistry
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
@ Copyright by Xiaoning Li 2014 
All Rights Reserved 
 ENGINEERED NANOPARTICLES FOR DETECTION AND TREATMENT 
OF BACTERIA AND BIOFILMS 
 
 
A Dissertation Presented  
By 
XIAONING LI 
 
 
 
 
 
Approved as to style and content by: 
       
Vincent M. Rotello, Chair 
       
Dhandapani Venkataraman, Member 
       
Michael J. Knapp, Member 
       
Harry Bermudez, Member 
       
Craig T. Martin, Department Head 
Department of Chemistry 
 DEDICATION 
 
To my parents and my love 
 
献给我最敬爱的父母和我的爱人！
v 
 
ACKNOWLEDGMENTS 
My PhD life has been an adventurous, challenging, yet rewarding journey, of which I 
have arrived to the last stop by writing this thesis. Chapters, words, and figures written here can 
only state my research achievement, but they are not able to reveal the tremendous help, support, 
and inspiration I have received from the people mentioned here. Without them, this journey 
would have been extremely difficult and dull. 
First, I would like to express my sincere and greatest gratitude to my advisor, Prof. 
Vincent M. Rotello, for his influential guidance and constant encouragement. He opened the gate 
to science for me, passed scientific vision to me, and taught me research skills. Most importantly, 
he showed me that all roads lead to science, for which Prof. Rotello has offered me the incredible 
freedom and flexibility to explore the vast world of science and to find my own path. I deeply 
appreciate him being my mentor and teacher and it is my great honor and fortune to work with 
him. 
I would like to acknowledge my dissertation committee members, Prof. Dhandapani 
Venkataraman (DV), Prof. Michael Knapp, and Prof. Harry Bermudez, for their constructive 
insights and academic support throughout this work. 
I am deeply appreciative to Prof. Margaret Riley, Dr. Y. S. Prakash, Prof. Xinrong Zhang, 
Dr. Fang Wen, Dr. Hao Kong, and Ms. Sandra Robinson for their advice, support, and especially 
expertise in their field to make our successful and productive research collaboration possible.  
I am truly thankful to all the past and present members in the Rotello group for their 
warm support and help all these years. They have been amazing colleagues, leaders, team 
members, teachers, mentees, and friends. In particular, I would like to thank Dr. Oscar Miranda 
and Dr. Chandra Subramani for introducing me to research and for sharing their research 
experience with me. I would also like to acknowledge the contributions that Dr. Miranda, Dr. 
vi 
 
Rana, Krish, Brian, Rubul, Daniel, Ali, Akash, Bo, Yi-Cheun, and Brad made to the work in this 
thesis. 
My warm and sincere thank also goes to all my friends who ensured my colorful and 
energetic life during my study in UMass Amherst: Jing, Yao, Zhongjing, Yuxi, Zhengjiang, Rui, 
NLe, Sung Tae, Youngdo, Chang Soo, Deb, Daniel, Ziwen, Tsukasa, Moumita, Vikas, Diego, 
Carol, Ari, and Mike. The joy we shared together, the tears we shed together, the time we spent 
together, and your helping hands on raining days will always be my treasured memory. 
Last but not least, I wish to give my sincerest and hearty thanks to my family for their 
endless love and unconditioned support. My grandparents and parents are the best teachers I 
could ever ask for. Their selfless love makes my wings so powerful that I can soar freely in this 
foreign sky. I am genuinely grateful to have Krish, my fiancée, to be my best friend and partner, 
who showed me my potential both in research and in life that I did not even know. His love, 
encouragement, and inspiration drove me to pursue my PhD degree and accomplish this thesis.  
 
vii 
 
ABSTRACT 
ENGINEERED NANOPARTICLES FOR DETECTION AND TREATMENT 
OF BACTERIA DN BIOFILMS 
SEPTEMBER 2014 
XIAONING LI 
B.S., UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Professor Vincent M. Rotello 
Rapid and sensitive detection and identification of bacteria woud control and prevent 
bacterial infection and disease, enhancing the likelihood of early diagnosis and treatment. 
Especially developing effective biosensor for identification of bacteria species involved in 
formation of biofilms, which cause chronic and persistent diseases, would promote diagnostic and 
therapeutic efficiency. Conventional detection methods are limited by sensitivity and required 
time. First part of my research has been focused on developing a rapid, simple, and sensitive 
biosensor aiming at portable device application for detection of bacteria in water samples. This 
sensor is able to detect bacteria at low concentration and generate colorimetric readouts that can 
be interpreted without aid of instrumentation. A prototype inkjet printed test strip is fabricated to 
demonstrate the low-cost and sensitive bacteria detecting approach. For detection and 
identification of the higher and more complex state of bacterial life, biofilms, I developed a multi-
channel biosensor to profile biofilms based on their global signature patterns. With the emergence 
of antibiotic especially multi-drug resistance in bacteria, prevention and detection is no longer 
efficient, and novel strategies are in great demand for treatment of these multi-drug resistant 
bacteria as well as bacterial biofilms which possess intrinsic antibiotic resistance. Thus the second 
part of my research is focused on exploring and tuning nanoparticles antimicrobial properties for 
treatment of bacteria and biofilms. 
viii 
 
TABLE OF CONTENTS 
Page 
ACKNOWLEDGMENTS ............................................................................................................. v 
ABSTRACT .................................................................................................................................. vii 
LIST OF TABLES ........................................................................................................................ xi 
LIST OF FIGURES ..................................................................................................................... xii 
CHAPTER  
1. INTRODUCTION...................................................................................................................... 1 
1.1 Global microbial threats ......................................................................................................... 1 
1.2 Biosensor ................................................................................................................................ 2 
1.3 Nanoparticles for biosensing .................................................................................................. 3 
1.4 Bacterial infections and treatment .......................................................................................... 6 
1.5 Bacterial resistance to antibiotics ........................................................................................... 7 
1.6 Strategies for discovery of novel antimicrobials .................................................................... 8 
1.7 Dissertation overview .......................................................................................................... 11 
1.8 References ............................................................................................................................ 12 
2. COLORIMETRIC DETECTION OF BACTERIA USING A HYBRID ENZYMATIC 
NANOCOMPOSITE SENSOR .................................................................................................. 17 
2.1 Introduction .......................................................................................................................... 17 
2.2 Results and Discussions ....................................................................................................... 18 
2.3 Conclusions .......................................................................................................................... 25 
2.4 Experimental methods.......................................................................................................... 26 
2.5 References ............................................................................................................................ 27 
3. ARTIFICIAL ENZYME MIMIC-BASED COLORIMETRIC SENSOR ......................... 31 
3.1 Introduction .......................................................................................................................... 31 
3.2 Results and discussion ......................................................................................................... 32 
3.3 Conclusions .......................................................................................................................... 43 
3.4 Experimental methods.......................................................................................................... 44 
3.5 Supplementary information.................................................................................................. 47 
3.6 References ............................................................................................................................ 48 
ix 
 
4. MULTICHANNEL SENSOR FOR RAPID IDENTIFICATION OF BIOFILMS 
FORMED BY BOTH LABORATORY AND PATHOGENIC BACTERIA ......................... 51 
4.1 Introduction .......................................................................................................................... 51 
4.2 Results and discussion ......................................................................................................... 53 
4.3 Conclusions .......................................................................................................................... 60 
4.4 Experimental methods.......................................................................................................... 61 
4.5 References ............................................................................................................................ 65 
5. FUNCTIONAL GOLD NANOPARTICLES AS POTENT ANTIMICROBIAL AGENTS 
AGAINST MULTI-DRUG-RESISTANT BACTERIA ............................................................ 69 
5.1 Introduction .......................................................................................................................... 69 
5.2 Results and discussion ......................................................................................................... 70 
5.3 Conclusions .......................................................................................................................... 75 
5.4 Experimental methods.......................................................................................................... 76 
5.5 References ............................................................................................................................ 78 
6. SURFACE FUNCTIONALITY CONTROLLED NP PENETRATION INTO 
BACTERIAL BIOFILMS ........................................................................................................... 81 
6.1 Introduction .......................................................................................................................... 81 
6.2 Results and discussion ......................................................................................................... 82 
6.3 Conclusions .......................................................................................................................... 88 
6.4 Experimental methods.......................................................................................................... 88 
6.5 Supplementary information.................................................................................................. 91 
6.6 References ............................................................................................................................ 97 
7. ANTIMICROBIAL GOLD NANOPARTICLES FOR INHIBITION AND REMOVAL 
OF BACTERIAL BIOFILMS .................................................................................................... 99 
7.1 Introduction .......................................................................................................................... 99 
7.2 Results and discussion ....................................................................................................... 102 
7.3. Conclusions ....................................................................................................................... 105 
7.4 Experimental methods........................................................................................................ 106 
7.5 References .......................................................................................................................... 108 
8. NANOPARTICLE-BASED CAPSULES FOR TREATMENT OF BIOFILMS ............. 110 
8.1 Introduction ........................................................................................................................ 110 
8.2 Results and discussion ....................................................................................................... 111 
8.3 Conclusions ........................................................................................................................ 118 
x 
 
8.4 Experimental methods ........................................................................................................ 118 
8.5 References .......................................................................................................................... 121 
BIBLIOGRAPHY ...................................................................................................................... 123 
xi 
 
LIST OF TABLES 
Table                 Page 
1.1. Characteristics, ligands and representative applications for various metal and semiconductor 
materials. Adapted from reference 14. ............................................................................................. 5 
1.2. Summary of selected studies concerning the antimicrobial effects of nanoparticles. Adapted 
from reference 66. .......................................................................................................................... 10 
3.1. Physical properties of analyte proteins. .................................................................................. 36 
3.2. Identifiation of 80 unknown protein samples with LDA using Fe3O4 NP sensor array. ......... 38 
3.3. Protein extinction coefficient. ................................................................................................. 46 
4.1. The binding parameters derived from the fitting of the fluorescence titration data. ............... 55 
4.2. The jackknifed classification accuracy based on the parts of the triple-channel fluorescence 
(R: tdTomato, G: EGFP, and B: EBFP2). ...................................................................................... 57 
4.3. Identification of 24 unknown biofilm samples. ...................................................................... 58 
4.4. Identification of 12 unknown co-culture samples. .................................................................. 60 
5.1. MIC values of C10-AuNP against uropathogens. ................................................................... 72 
xii 
 
LIST OF FIGURES 
Figure                 Page 
1.1. Schematic illustration of a general biosensor design including bioreceptor, transducer, 
amplifier, and data process. ............................................................................................................. 2 
1.2. A sandwich bioaffinity assay for detection of galactomannan. Analyte galactomanna is 
captured by the antibody EB-A2 receptor then is labeled by another layer of EB-A2 receptors 
plus peroxidase. Signals were then generated and amplified by peroxidase catalyzed chromogenic 
reaction. Adapted from reference 8.................................................................................................. 3 
1.3. Schematic illustration of nanoparticle size compared to biomolecules and bio-species. .......... 4 
1.4. A NP-based sandwich bioaffinity assay for detection of protein. By conjugation with NP, 
number of Cy5 labeled secondary antibody increased compared to the original sandwich assay 
design, hence improving biosensor sensitivity. Adapted from reference 9. .................................... 4 
1.5. Colorimetric detection of Hg2+ using DNA functionalized gold nanoparticles. Thymidine-
Hg2+-thymidine coordination chemistry is exploited and results in gold nanoparticle aggregation. 
The aggregation of gold nanoparticles of appropriate sizes (diameter bigger than 3.5 nm) induces 
interparticle surface plasmon coupling, resulting a visible color change from red to blue. This 
phenomenon provides a practical platform for absorption-based colorimetric sensing. Adapted 
from reference 12. ............................................................................................................................ 5 
1.6. Schematic illustration of non-healing wounds caused by bacterial biofilm. Adapted from 
reference 18. ..................................................................................................................................... 7 
2.1. Schematic illustration of the enzyme-amplified sensing of bacteria, showing the relative sizes 
of 2 nm core diameter particles and β-Gal. .................................................................................... 18 
2.2. Molecular structure of ligands on the selected cationic functionalized gold nanoparticles. ... 19 
2.3.  Inhibition of activity assay of β-Gal (0.5 nM) with 5 mM substrate CPRG upon addition of 
NP1-NP4. ...................................................................................................................................... 19 
2.4. Inhibition of β-Gal before (“ON”) and after (“OFF”) addition of NP2. And the “OFF” state is 
the concentration chosen to construct the colorimetric biosensor. ................................................ 20 
2.5. Limit of detection of E. coli using -Gal/NP2 nanocomposite. Kinetic absorbance response 
upon addition of different bacteria concentrations, as control -Gal/NP2 nanocomposite was used 
without bacteria.  At the top, microplate wells showing the color change upon variation of 
bacteria concentrations. .................................................................................................................. 21 
2.6. Enzymatic inhibition-colorimetric assay of β-Gal (15 nM) against 25 mM substrate CPRG 
upon addition of cationic, anionic and neutral nanoparticles. a. carboxylate (NPCO2), b. hydroxyl 
(NPTEG), and c. quaternary amine functionalized gold nanoparticles on a platform testing. Inset 
shows total inhibition for the positive nanoparticle NP2 at 80 nM, while no inhibition was 
observed for both the anionic and neutral AuNPs even at 160 nM. .............................................. 22 
xiii 
 
2.7. Schematic illustration of the RGB colorimetric analysis to monitor color changes on the 
GF/B filter paper spot at pH 7.4. a. image of the enzymatic activity response-colorimetric assay 
of the β-Gal-NP2 complex upon addition of E. coli at different concentration, CPRG substrate 
was used as a control. b. red, green, and blue channels obtained from the original sample a to 
differentiate between bacteria concentration. c. the extracted values of red, green, and blue 
channel from the original data a. This process is repeated three times for each measurement in a 
series of images. ............................................................................................................................. 23 
2.8. Schematic illustration of inkjet printing of the NP-based enzymatic amplified bacteria test 
strips. Inks were printing in a checker pattern to ensure no interaction before use. ...................... 24 
2.9. Sensitivity of the colorimetric sensor printed by an inkjet printer. The unit of the 
concentrations above the strips is cfu/mL. ..................................................................................... 25 
3.1. a. Structures of Dop-Fe3O4 and TMA-Fe3O4. b. Hydrodynamic diameter and zeta potential of 
Fe3O4 NPs in 5 mM CH3COONa buffer at pH 5.0. ....................................................................... 32 
3.2. Schematic illustration of the Fe3O4 NP enzyme mimetic amplified colorimetric sensing of 
proteins. .......................................................................................................................................... 33 
3.3. Normalized OD at 420 nm upon protein addition with fixed NPs concentration (25 µg/mL). a. 
Concentration dependent OD curve of lipase. b. Normalized OD curve of lysozyme with modest 
permutation. Results are average of three measurements and error bars are standard deviation. .. 34 
3.4. Hydrodynamic diameters of a. lipase, functionalized Fe3O4 NP, and lipase-NP complex, and 
b. lysozyme, functionalized Fe3O4 NP, lysozyme-NP complex. Results are average of three 
measurements and error bars are standard deviation. The NP concentration used in the size 
measurement is 250 µg/mL and the protein is at a concentration of 500 nM. ............................... 35 
3.5. Array-based sensing of ten proteins. a. Photograph of the color change upon addition of 
protein solutions at 50 nM. b. OD response (OD/OD0 at 420 nm) patterns in the presence of 
proteins at 50 nM (responses are an average of five measurements and the error bars are the 
standard deviation). c. Canonical score plot for the OD response patterns as obtained from LDA 
with 95% confidence ellipses. ........................................................................................................ 37 
3.6. Sensitivity of the Fe3O4 NP colorimetric in solution. The unit of the concentrations above 
the strips is cfu/mL......................................................................................................................... 40 
3.7. Schematic illustration of Fe3O4 NP-based inkjet printed test strip fabrication. ...................... 41 
3.S1. Normalized OD upon different hemoglobin concentrations with the fixed NPs concentration 
(25 µg/mL). OD curve of hemoglobin is concentration dependant in an increasing fashion till a 
saturated point. ............................................................................................................................... 47 
3.S2. Normalized OD at 420 nm of Fe3O4 NPs (25 μg/mL), hemoglobin (50 nM), and 
hemoglobin-Fe3O4 NP complex. The catalytic activity of Hem-Fe3O4 NP complex is higher than 
that of Fe3O4 NPs but is lower than the sum of Fe3O4 NP and hemoglobin. ................................. 48 
 
xiv 
 
3.S3. Photographs of color changes in the titration studies of lipase, lysozyme, and hemoglobin. 
Images were obtained by scanning right after reading OD at 420 nm. The peroxidase-like activity 
of both NPs (Dop- and TMA-Fe3O4) is inhibited by lipase and the green color intensity of the 
product from the catalyzed hydrolysis of substrate ABTS decreases as lipase concentration 
increases. The colorimetric signals have no significant differences in a wide range of lysozyme 
concentrations. The catalyzed colorimetric reaction rate is increased in the presence of 
hemoglobin, giving increased intensity of the green color in higher concentrations of hemoglobin.
 ....................................................................................................................................................... 48 
4.1. Schematic illustration of the multichannel sensing. The sensor is composed with AuNP-
fluorescent protein conjugates which will be disrupted in the presence of biofilms. The disruption 
turns on fluorescence and gives different colored fluorescence patterns for biofilm identification.
 ....................................................................................................................................................... 52 
4.2. a. Molecular structure of NP surface ligand. b. The absorption and emission spectra of the 
three fluorescent proteins. .............................................................................................................. 53 
4.3. a. The sensor elements and molecular structures of the functional ligands of NP1 and NP2. 
Fluorescence titration with b. NP1, c. NP2, d. an equal molar mixture of NP1 and NP2. Each 
value is an average of three replicates and the error bars are standard deviations. ........................ 54 
4.4. Detection and identification of biofilms formed by four laboratory strains and two 
uropathogenic strains. Triple-channel fluorescence response patterns in the presence of biofilms. 
I0 is the fluorescence intensity in the absence of biofilms. Each value is an average of six 
replicates and the error bars are standard deviations. .................................................................... 56 
4.5. Canonical score plot of the fluorescence response patterns as obtained by LDA against the 
six bacterial biofilms. ..................................................................................................................... 57 
4.6. Detection and identification of biofilms grown on 3T3 fibroblast cells. a. Triple-channel 
fluorescence response patterns in the presence of biofilms grown on fibroblast cells and 3T3 
fibroblast cells alone. I0 is the fluorescence intensity in the absence of biofilms or 3T3 cells. Each 
value is an average of six replicates and the error bars are standard deviations. b. LDA canonical 
score plot of the fluorescence response patterns. ........................................................................... 59 
4.7. DLS size distribution of NP1 and NP2. .................................................................................. 62 
4.8. Zeta potential distribution of NP1 and NP2. ........................................................................... 62 
5.1. Molecular structures of functional ligands on AuNPs. ........................................................... 70 
5.2. MIC values of AuNPs bearing different hydrophobic surface ligands against laboratory E. 
coli. Log P represents the calculated hydrophobic values of the end groups. ............................... 71 
5.3. CLSM images of PI staining showing NP-induced bacterial cell membrane damage. Scale bar 
is 5 µm. .......................................................................................................................................... 74 
5.4. Hemolytic activity of C10-AuNPs at different concentrations. The red cross is an estimate of 
HC 50, the concentration to lyse 50% of human red blood cells, which turns out to be around 402 
nM. ................................................................................................................................................. 74 
xv 
 
5.5. 3T3 fibroblast cell percent viability when incubated with different concentrations of C10-
AuNP. ............................................................................................................................................ 75 
6.1. Schematic illustration of surface functionality controlled QD penetration into biofilms. 
Neutral and anionic QDs cannot penetrate into E. coli biofilms, but cationic QDs can. ............... 82 
6.2. a. Molecular structure of functionalized QD surface ligands. PEG-QD is neutral, COOH-QD 
is anionic, and TTMA-QD and Hexyl-QD are cationic. b. Physical properties of functionalized 
QDs. ............................................................................................................................................... 83 
6.3. Representative 3D projection of image z-stacks showing distribution of bacterial cells (red) 
in E.coli biofilms and QDs (green): a, PEG-QD; b, COOH-QD; c, TTMA-QD; d, Hexyl-QD. 
Upper panels are projections at 247° angle turning along Y axis and lower panels are at 270° 
angle turning along Y axis. Scale bar is 20 μm. e and f are plot profiles of the three linear 
selection (yellow lines) in c and d, illustrating horizontal distribution of e TTMA-QD and f 
Hexyl-QD. ...................................................................................................................................... 84 
6.4. Zoomed CLSM images of biofilms after 1hr incubation with QDs, showing association sites 
of a TTMA-QD and b Hexyl-QD. The scale bar is 5 μm. ............................................................. 85 
6.5. Integrated intensity of a TTMA-QD and biofilm and b Hexyl-QD and biofilm after 1hr 
incubation. The y-axis, normalized intensity, is the integrated QD intensity normalized by the 
integrated biofilm intensity. The x-axis is the depth of penetration of biofilms, where 0 μm 
represents the top and 10 μm represents the bottom. The data are average of three image stacks. 
Error bars are standard deviation. .................................................................................................. 86 
6.6. The penetration profile of TTMA-QD 1hr (square, solid), Hexyl-QD 1hr (circle, solid), 
TTMA-QD 3hr (square, empty), and Hexyl-QD 3hr (circle, empty). The y-axis, normalized 
intensity, is the integrated QD intensity normalized by the integrated biofilm intensity. The x-axis 
is the depth of penetration of biofilms, where 0 μm represents the top and 10 μm represents the 
bottom. The data are average of three image stacks. ..................................................................... 87 
6.7. a. Structures of the ligands used in the studies. b. Synthetic route of DHLA-TEG-COOH 
ligand. Reagents and conditions: (i) EDC, HOBt, DIPEA, DCM, r.t., 24 h; (ii) DMAP, DIPEA, 
succinic anhydride, THF, r.t., 24 h; (iii) NaBH4, EtOH/ H2O, r.t., 1 h .......................................... 90 
6.S1. Representative CLSM image slices of z-stack with a 0.4 μm interval showing bacterial cells 
(red) in E.coli biofilms and distribution of PEG-QD. The 3D projection of these slices is 
displayed in Figure 6.3 a. for a clear demonstration. The absence of green fluorescence from 
PEG-QD indicates no neutral QD absorbance or penetration occurred within the one hour 
incubation time. The scale bar is 20 µm. ....................................................................................... 91 
6.S2. Representative CLSM image slices of z-stack with a 0.4 μm interval showing bacterial cells 
(red) in E.coli biofilms and distribution of COOH-QD. The 3D projection of these slices is 
displayed in Figure 6.3 b. for a clearer demonstration. The absence of green fluorescence from 
COOH-QD indicates no anionic QD absorbance or penetration occurred within the one hour 
incubation time. The scale bar is 20 µm ........................................................................................ 92 
6.S3. CLSM image stacks used for analysis of TTMA-QD penetration profile after 1 hr 
incubation. The scale bar in these images is 20 µm ....................................................................... 93 
xvi 
 
6.S4. CLSM image stacks used for analysis of Hexyl-QD penetration profile after 1 hr incubation. 
The scale bar in these images is 20 µm. ......................................................................................... 94 
6.S5. CLSM image stacks used for analysis of TTMA-QD penetration profile after 3 hr 
incubation. The scale bar in these images is 20 µm. ...................................................................... 95 
6.S6. CLSM image stacks used for analysis of Hexyl-QD penetration profile after 3 hr incubation. 
The scale bar in these images is 20 µm. ......................................................................................... 96 
7.1. Three hypotheses for mechanisms of antibiotic resistance in biofilms. The attachment surface 
is shown at the bottom and the aqueous phase containing the antibiotic at the top. Adapted from 
reference 10. ................................................................................................................................. 100 
7.2. Molecular structure of functionalized cationic C10-AuNP. ................................................. 102 
7.3. Inhibition of a. one-day old biofilm and b. two-day old biofilms of E. coli in the presence of 
C10-AuNP (black solid square) and kanamycin (black empty square) and P. aeruginosa in the 
presence of C10-AuNP (red solid triangle) and kanamycin (red empty triangle). Data are average 
of triplicates and error bars are standard deviation. ..................................................................... 103 
7.4. The killing effect of C10-AuNP against one-day old P. aeruginosa biofilm. The biofilms 
were treated with AuNP for one day, and %killing is calculated by 100% minus the %viability of 
remaining biofilms after treatment. Data are average of triplicates and error bars are standard 
deviation. ...................................................................................................................................... 105 
8.1. Schematic illustration of SiO2 NP-based essential oil capsules. ........................................... 111 
8.2. Viability of a. one day-old E. coli biofilms and b. one day-old P. aeruginosa biofilms after 
three hour treatment with different concentrations of capsules containing peppermint oil and 
cinnamaldehyde (C-Cap, black), capsules containing only peppermint oil (P-Cap, red), SiO2 NP 
(green), and peppermint oil (Ppmt Oil, blue). Data are average of triplicates and error bars are 
standard deviation. ....................................................................................................................... 112 
8.3. Viability of a. one day-old E. coli biofilms and b. one day-old P. aeruginosa biofilms after 
one day treatment with different concentrations of capsules containing peppermint oil and 
cinnamaldehyde (C-Cap, black), capsules containing only peppermint oil (P-Cap, red), SiO2 NP 
(green), and peppermint oil (Ppmt Oil, blue). Data are average of triplicates and error bars are 
standard deviation. ....................................................................................................................... 113 
8.4. Viability of a. three day-old E. coli biofilms and b. three day-old P. aeruginosa biofilms after 
one day treatment with different concentrations of capsules containing peppermint oil and 
cinnamaldehyde (C-Cap, black), capsules containing only peppermint oil (P-Cap, red), SiO2 NP 
(green), and peppermint oil (Ppmt Oil, blue). Data are average of triplicates and error bars are 
standard deviation. ....................................................................................................................... 114 
8.5. Viability of 3T3 fibroblast cell and E. coli biofilms in the co-culture model after three hour 
treatment with a. C-Cap, b. P-Cap, c. SiO2 NP, and d. Peppermint oil. The left y axis represents 
the viability of 3T3 cells (blue histogram) and data are average of triplicates and error bars are 
standard deviation. The right y axis represents the log10cfu of viable colonies in E. coli biofilms 
and data are average of duplicates and error bars are standard deviation. ................................... 116 
xvii 
 
8.6. Representative three dimensional projections of confocal laser scanning microscopic z-stack 
images of E. coli biofilms (red) after incubation with a. C-Cap, b. P-Cap, and c. SiO2 NP alone. 
The left panels show the green fluorescence from FITC-labeled-SiO2 NP. The middle panels 
show the red fluorescence from crimson-expressing E. coli biofilm. The right panels show 
overlay of the corresponding left and middle panel images. The z-stack images were taken at a 
o.4 µm intervals. The scale bar is 20 µm ..................................................................................... 117 
 1 
 
CHAPTER 1 
INTRODUCTION 
1.1 Global microbial threats 
 Microbial infections cause 300 million cases of severe illness every year, and 16 million 
people including 2 million children are estimated to be killed by infectious diseases every year.
1
 
Recent outbreaks, such as Escherichia coli in Germany and the New Delhi Metallo-beta-
lactamase-expressing “superbug” in Asia, remind us that microbes are still one of the greatest 
threats to public health and wellness on a global scale. As a result, rapid detection of 
microorganisms, especially bacteria, is a key requirement in environmental monitoring, water and 
food safety, and clinical diagnosis and treatment. 
Conventional method for detection and identification of bacteria is plating and culture.
2
  
After sampling, it generally requires at least 24 hours for analysis and demands selective and 
differential mediums during culture.
3
 Additionally, due to the low sensitivity and limited 
countable colonies required, samples often need to be collected in large volumes. However, 
bacteria number can change very rapidly and greatly during the culture and analysis time, which 
may result in incorrect or belated assessment. Since short term peaks of bacteria concentration 
can lead to considerably increased outbreaks of disease, rapid and sensitive methods for detection 
of bacteria are in great demand to address the urgency need for monitoring food/water quality as 
well as clinical diagnosis.  
Quantitative polymerase chain reaction (q-PCR) allows amplification and simultaneous 
quantification of target bacterial DNA, providing a more sensitive technique capable of detecting 
and identifying bacteria in less than 24 hours.
4
 This molecular technique has been eventually 
adapted by the U.S. Environmental Protection Agency and clinical diagnosis. Similarly, other 
methods have been proposed and investigated by researchers using high technology, such as 
luminescence,
5
 immunological methods,
6
 and mass spectrometry.
7
 Each of these systems has 
 2 
 
advantages and offers new aspects into promoting rapid microbial detection. However, the 
requirement of expensive instrument and trained personnel may substantially limit their 
application, especially for on-site detection and widespread application in emerging countries 
where bacteria-contaminated water and food take a majority part of global deaths caused by 
bacterial diseases. Therefore, technological platforms that possess rapid, sensitive, simple, and 
potentially low-cost detection features are still the focus of pioneer research. 
1.2 Biosensor 
A biosensor is generally defined as a device that utilizes biological components to detect 
a target substance, often a biological analyte. The essential device-based detection technique of 
biosensors makes them a more suitable approach for on-site application. A biosensor usually 
consists of a receptor for recognition of analytes and a transducer for transduction of signals to 
interpretation (Figure 1.1).  
 
Figure 1.1. Schematic illustration of a general biosensor design including bioreceptor, transducer, 
amplifier, and data process. 
In a biosensor, a receptor is mostly a biological species (e.g., an enzyme, an antibody, or 
a nucleic acid) or a biological living system (e.g., cells or microorganisms), and such bioreceptors 
can be incorporated in the sampling portion of a biosensor via either covalent or non-covalent 
attachment. Analytes are often recognized by interaction with receptors through 
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biochemical/biophysical mechanisms. And the interaction event between analytes and receptors is 
converted by transducer into a measurable effect, such as an electrochemical, mass-sensitive, or 
optical signal. 
  The two key steps involved in the detection process using a biosensor are analyte 
recognition and signal transduction. The sensitivity of a biosensor is therefore dependent upon 
these two key designs. One commonly employed strategy to increase biosensor sensitivity is 
signal amplification during/after signal transduction process.  For example, optical or electronic 
sandwich bioaffinity assays capture and recognize analytes on one layer of receptors, followed by 
labeling of analytes with another layer of secondary receptors/amplifiers which then generate 
amplified signals (Figure 1.2).
8
 The challenge in these approaches is the disadvantages of 
capturing a small number of labels per binding event. Therefore, innovative materials and 
platforms are needed in order to achieve ultrahigh sensitivity during analyte recognition process. 
 
 
Figure 1.2. A sandwich bioaffinity assay for detection of galactomannan. Analyte galactomanna 
is captured by the antibody EB-A2 receptor then is labeled by another layer of EB-A2 receptors 
plus peroxidase. Signals were then generated and amplified by peroxidase catalyzed chromogenic 
reaction. Adapted from reference 8.  
1.3 Nanoparticles for biosensing 
The distinctive physical and chemical properties of nanoscale particles offer unique 
prospects for designing highly sensitive receptors in biorecognition process, potentially 
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increasing biosensor sensitivity (Figure 1.3). First, the tiny size and large surface-to-volume ratio 
of NPs guarantees increased receptor-analyte interaction, amplifying number of binding events 
(Figure 1.4).
9
 Additionally, surface functionalization of NPs can provide stable, sensitive, and 
specific or selective recognition elements of interest in biosensor design.
10
 
 
 
Figure 1.3. Schematic illustration of nanoparticle size compared to biomolecules and bio-species.  
 
 
Figure 1.4. A NP-based sandwich bioaffinity assay for detection of protein. By conjugation with 
NP, number of Cy5 labeled secondary antibody increased compared to the original sandwich 
assay design, hence improving biosensor sensitivity. Adapted from reference 9. 
Furthermore, NPs possess distinctive attributes such as optical, photophyscial, electronic, 
and catalytic properties, which make them ideal labels for the biorecognition process. These 
properties can be further tuned by size, shape, dimensions, and compositions. In addition, the 
nanoscale size of NPs dictates that their properties can be strongly affected by the binding with 
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analyte molecules,
11
 providing pronounced affect for signal generation and transduction (Figure 
1.5).
12,13
  
 
 
Figure 1.5. Colorimetric detection of Hg2+ using DNA functionalized gold nanoparticles. 
Thymidine-Hg2+-thymidine coordination chemistry is exploited and results in gold nanoparticle 
aggregation. The aggregation of gold nanoparticles of appropriate sizes (diameter bigger than 3.5 
nm) induces interparticle surface plasmon coupling, resulting a visible color change from red to 
blue. This phenomenon provides a practical platform for absorption-based colorimetric sensing. 
Adapted from reference 12.  
Given the enormous amplification afforded by NPs as well as the NP size-dependent 
properties, such as enhanced surface activity, surface plasmon resonance, quantum confinement, 
and superparamagnetism, nanoparticles make remarkable platforms for designing novel and 
highly sensitive biosensors (Table 1.1).
14
 More importantly, by engineering core composition, 
size, and shape, NP properties can be tuned to give a variety of signal types for amplification and 
outputs. Similarly, engineered NPs can afford multifunction, presenting various yet controllable 
interaction profiles on NP surface to meet requirements of different analyte target. Hence, the use 
of properly engineered NPs could realize the high demand of rapid, sensitive, and simple methods 
for detection of bacteria. 
Table 1.1. Characteristics, ligands and representative applications for various metal and 
semiconductor materials. Adapted from reference 14. 
Core 
materials 
Characteristics Ligand(s) Applications 
 6 
 
Au Optical absorption, fluorescence and 
fluorescence quenching, stability 
Thiol, disulfide, 
phosphine, amine 
Biomolecular recognition, 
delivery, sensing 
Ag Surface-enhanced fluorescence Thiol Sensing 
Pt Catalytic property Thiol, phosphine, 
amine, isocyanide 
Bio-catalyst, sensing 
CdSe Luminescence, photo-stability Thiol, phosphine, 
pyridine 
Imaging, sensing 
Fe2O3 Magnetic property Diol, dopamine 
derivative, amine 
MIR imaging and biomolecule 
purification  
SiO2 Biocompatibility Alkoxysilane Biocompatible by surface 
coating 
 
1.4 Bacterial infections and treatment 
Pathogenic bacteria are referred to those that cause or are capable of causing disease. 
Some pathogens are unequivocally pathogenic, whereas others are generally harmless and they 
cause disease only under certain conditions, for example, when being introduced into a normally 
sterile body site, or infection of an immunocompromised host.
15
 Pathogenic bacteria can enter the 
host body through a variety of means, including inhalation, ingestion, or sexual contact. Upon 
evasion of host primary defense, bacteria usually adhere to host cells and proliferate, causing 
infections by damaging host cells via toxins or an inflammatory response. Furthermore, if 
bacteria successfully evade host secondary defenses, infections, in turn, can have severe 
consequences, leading to serious bacterial diseases and even life-threatening complications, such 
as sepsis, organ failure, toxic shock syndrome, and death.
16
 In some cases, bacterial infections can 
result in chronic disease state, where the involved bacterial colonization often develops into a 
biofilm, a complex three-dimensional bacterial community.
17
 The biofilm-associated diseases are 
clinically more challenging than acute bacterial infections in both diagnosis and treatment (Figure 
1.6).
18
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Figure 1.6. Schematic illustration of non-healing wounds caused by bacterial biofilm. Adapted 
from reference 18. 
Bacterial infections are generally treated with antibiotics, of which the selective toxicity 
ensures killing (bactericidal) or inhibiting the growth and spread (bacteriostatic) of the pathogenic 
bacteria without harming the cells of the host. Antibiotics can be organized into six families – the 
penicillins, cephalosporins, tetracyclines, aminoglycosides, macrolides, and fluoroquinolones, 
plus other agents which include vancomycin and trimethoprim-sulfamethoxazole.
19
 The 
mechanisms of how these antibiotics act against bacteria include (i) inhibition of bacterial cell 
wall synthesis (penicillins, vancomycin, etc),
20
 (ii) inhibition of protein synthesis (tetracyclines, 
macrolides, etc),
21
 (iii) alteration of cell membrane (polymycins, etc),
22
 (iv) inhibition of nucleic 
acid synthesis (quinolones, rifampin, etc),
23
 and (v) antimetabolite activity (trimethoprim, etc).
24
 
1.5 Bacterial resistance to antibiotics 
Antibiotics are among the most commonly prescribed drugs, and many of the 
prescriptions are for patients who do not need or cannot be treated effectively as prescribed.
 25
 
Antibiotics are widely used in food animals as well to prevent, control, and treat diseases, and this 
practice is believed to be capable of promoting the growth and production of food.
26
 The 
widespread use of antibiotics has caused the emergence of resistance, even multidrug resistance 
(MDR) in bacteria.
27
 Antibiotic resistance has become a worldwide problem, as many forms of 
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resistance spread can cross international boundaries and even between continents with ease and 
remarkable speed. 
Bacterial resistance to antibiotics can spread both genetically and environmentally. 
Genetically, antibiotic resistance transfers through bacteria population “vertically”, when new 
generations of bacteria inherit resistance genes from parent bacteria,
28
 as well as “horizontally”, 
when bacteria share or exchange resistance-encoding genetic materials with neighboring 
bacteria.
29
 Environmentally, antibiotic resistance spreads as bacteria travel from place to place via 
air, water, and hosts (human, animals, etc) contact. Among all these paths, horizontal gene 
transfer is the primary reason for bacterial antibiotic resistance,
30
 and three mechanisms for 
horizontal gene transfer have been identified: transformation, transduction, and conjugation. Due 
to these mechanisms, horizontal gene transfer happens frequently in the general community, and 
particularly in healthcare setting, such as hospitals and nursing homes, where most deaths related 
to antibiotic resistance occur.  
According to Center for Disease Control and Prevention, at least 2 million people acquire 
serious infections with MDR bacteria.
31
 In most cases of antibiotic-resistant infections, it requires 
prolonged treatments, extended hospital stays, necessitate additional healthcare use, resulting in 
great disabilities and deaths. At least of 23,000 people die each year as a direct result from 
antibiotic-resistant infections, and many more from complications by an antibiotic-resistant 
infection. Moreover, economic cost of antibiotic resistance can be as high as $20 billion in direct 
healthcare, with additional costs to society for lost productivity as high as $35 billion a year.
32
 
1.6 Strategies for discovery of novel antimicrobials 
The ruthless spread of antibiotic resistance in bacteria, coupled with insufficient 
investment in antibacterial research, has led to a steady decline in the efficacy of current 
treatments and a lack of new drug families with which to complement their use or replace them. 
Hence, there is urgent and undeniable need for new antibacterial research. Perspective strategies 
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for discovery of novel antimicrobials usually include new antibacterials from natural products, 
modification of existing classes, and antimicrobial peptides.
33
  
Historically, the screening of natural products obtained from microbial sources revealed 
many and successful antibacterial discoveries. Penicillin, for instance, was uncovered and derived 
from Penicillium fungi. However, since many of the easily accessible compounds have been 
explored, it become more challenging and requires technique improvement (culture the 
“uncultured” soil bacteria, metagenomics, etc) for future investigation in natural products.34  
Medicinal chemistry has been adapted as a powerful tool to improve the activity or 
profile of existing antibiotic classes.
35
 By logical and systematic modifications, the next 
generation can increase potency and activity spectrum. Cephalosporins, β-lactam antibiotics, 
belong to one class of antibiotics that has been subjected to extensive medicinal chemistry 
examination. In this class, first-generation agents are active primarily against Gram-positive 
organisms and have limited activity against Gram-negative bacilli. Second- and third generation 
displayed activity against some Gram-negative organisms. Fourth-generation Cefepime feature 
extended spectrum of activity against both Gram-positive and Gram-negative bacteria, and it is 
active as well against some strains producing β-lactamase enzymes that inactivates β-lactam 
antibiotics.
36
  Due to the time-consuming and laborious synthetic requirements, the medicinal 
chemistry research on developing novel antibiotics is typically carried out in pharmaceutical 
companies, where such investigations have become exceedingly unattractive investments.
37
  
 Antimicrobial peptides are host-defense molecules produced by all living organisms. 
These evolutionary conserved peptides bear an overall positive charge and have both a 
hydrophobic and hydrophilic side, enabling the molecule to enter lipid-rich membrane of target 
bacterial cells.
38
 Antimicrobial peptides possess favorable qualities as novel antibacterials, such 
as reduced propensity to engender resistance and anti-inflammatory and anti-endotoxin activities. 
Polymyxins, cationic lipopeptides, have been approved for clinical use and applied to MDR-
bacterial infections.
39
 Despite their attractive properties, antimicrobial peptides are costly to 
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synthesize, and their susceptibility to proteolytic enzymes lead to a short half-life in vivo.
40
 These 
challenging difficulties need to be addressed for future development of antimicrobial peptides.
41
 
Table 1.2. Summary of selected studies concerning the antimicrobial effects of nanoparticles. 
Adapted from reference 66. 
 
Nanotechnology has introduced nanoparticles (NPs) as a new paradigm in therapeutic 
applications with their unique properties.
42
 For example, NP size range is commensurate with 
biomolecular and bacterial cellular systems, providing additional interactions to small molecule 
antibiotics,
43
 which can be controlled by tailoring NP interface.
44
 Also, NPs being slightly larger 
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than drug efflux pumps, potentially reduces the efflux-mediated extrusion.
45 , 46
 These 
characteristic features imply that NPs may interact with and penetrate into bacterial cells with 
unique bacteriostatic and bactericidal mechanisms.
47,48
 Presumably, this implication allows a way 
to address the common mechanisms of antibiotic resistance, such as permeability regulation,
49,50
 
multi-drug efflux pumps,
51 , 52
 antibiotic degradation,
53 , 54
 and alteration of target site binding 
affinity.
55,56
 Thus, NPs offer a new defense pathway to develop novel antibiotics to (i) combat 
multi-drug resistant (MDR) bacteria and (ii) lower the pace of resistance evolution by bacteria.
 
57,58,59
 Following this strategy, photocatalytic NPs,
60,61
 polycationic NPs,
62,63
 and ROS-stimulating 
metal and metal oxide NPs
64,65
 have been used to impart antimicrobial efficacy (Table 1.2).
66
 
1.7 Dissertation overview 
It has been shown that engineering nanoparticle surface can enhance and tailor 
interactions with bacterial cells. These interactions between NPs and bacteria have not yet been 
fully understood, but they exhibit potential pathways for application of microbial detection and 
treatment. In this thesis, engineered nanoparticles are used to address the urgent need of and 
rising challenges in rapid and sensitive detection of bacteria as well as novel antibacterials to 
combat MDR bacteria. The detection and treatment possibility of a higher and more complex 
state of microbial life, biofilms, is also explored in this thesis. First, in Chapter 2, I will describe a 
gold nanoparticle-based strategy for rapid colorimetric detection of bacteria using enzymatic 
amplification. This sensing system is proved to reach clinical and environmental-relevant 
sensitivity within minutes, giving colorimetric readouts. Such system is applied on a paper-based 
format to explore the potential of fabricating test strips for detection of bacteria in water samples. 
The high sensitivity, rapid detection speed, and colorimetric readouts demonstrate 
promising application of the NP-enzyme biosensor. In Chapter 3, I will show the improvement 
based on the NP-enzyme biosensor. To address stability and shelf-life issues related to the use of 
natural enzymes, engineered Fe3O4 nanoparticles are employed as synthetic enzyme mimics.  I 
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will show the capability and sensitivity of this synthetic enzyme mimic-based colorimetric sensor 
using proteins as model analytes first, and then I will discuss how this method can be used in 
detection of bacteria. 
In Chapter 4, I will describe a gold nanoparticle-constructed multi-channel sensor for 
detection and identification of biofilms. This approach is the first to detect and identify biofilms 
based-on their overall physiological signatures using a nanobiosensor. Using this approach, I was 
able to identify biofilms formed by laboratory and clinical isolated uropathgenic strains. The 
sensor was further demonstrated to be capable of discriminating biofilms on an in vitro wound 
model. 
In Chapter 5, I will demonstrate that by tailoring surface chemistry, gold nanoparticles 
can be used as potent antimicrobial agents against MDR bacteria. I will further discuss the found 
NP surface ligand structure and activity relationship, which reveals a new aspect to design and 
construct antimicrobial gold nanoparticles.  
When a bacterial infection develops into biofilm-associated infection, it become much 
more difficult to treat due to raised resistance and protection from biofilm matrix. In Chapter 6 
and Chapter 7, I will demonstrate how engineered NPs can be used as a probe to penetrate 
biofilms and how properly selected NPs can be used as promising candidates for prevention and 
treatment of bioflms. I will further show NP-assemble essential oil containing capsules for 
selective eradication of biofilms on an in vitro wound model. These results indicate that NPs can 
be used as anti-biofilm agents besides being antibacterials, making them attractive candidates in 
the battle between technology and evolution of bacterial resistance.  
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CHAPTER 2 
COLORIMETRIC DETECTION OF BACTERIA USING A HYBRID 
ENZYMATIC NANOCOMPOSITE SENSOR 
2.1 Introduction 
Bacterial infection causes millions of severe illnesses each year,
1
 and is estimated to kill 
over 2 million children every year.
2
 The great majority of these illnesses and deaths occur in 
developing countries where drinking water and food are frequently contaminated with bacteria.
3
 
Several techniques
4
 are available for bacteria detection and identification, including i) plating and 
culturing,
 5
ii) luminescence,
6
 iii) immunological approaches,
7
 iv) nucleic acid probe-based 
methods (PCR, LCR),
8 
v) mass spectrometry,
 9 
 vi) microarrays,
10
 and vii) biosensors.
11
 Each of 
these systems has its own advantages; however the utility of these methods is generally limited by 
high cost for use and requirement for trained personnel.  
Recent advances in nanotechnology have enabled the development of new diagnostic 
platforms for sensitive and rapid bacteria detection. For example, Ji et.al.
12
 used positively-
charged amine-terminated polyamidoamine dendrimers to capture bacteria, reporting a sensitivity 
as low as 1 x 10
4 
cfu/mL.
13
 Gold nanoparticles (AuNPs) have likewise been employed for 
detection of bacteria,
14
 virus,
15
 cancer cells,
16
 and proteins.
17
 In 2005, Murphy et al.
18
  showed 
that CTAB (cetyltrimethylammonium bromide)-functionalized gold nanorods or nanospheres can 
conformally deposit to form monolayer on Bacillus cereus by strong electrostatic interaction. 
More recently, our group
 
has demonstrated how electrostatic assembly can be used for bacteria 
sensing through a nanoparticle-fluorescent polymer conjugate system at 2×10
5
 cfu/mL.  
There are two key issues in designing effective sensors for pathogen detection in the field. 
First, the limits of detection (LOD) required for application in either environmental testing
19
 or 
clinical applications
20
 is 10
4
-10
2
 cfu/mL, Second, readout should not require expensive 
instrumentation. Therefore, in this chapter, we developed a hybrid colorimetric enzymatic 
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nanocomposite biosensor to address these issues. This biosensor uses enzyme amplification to 
provide high sensitivity for the detection of pathogens in aqueous solutions. The efficacy of this 
system was demonstrated in both solution and test strip format.  
The sensor design features three main components: a) -Galactosidase (-Gal),21  an 
anionic enzyme (pI 4.6) for signal amplification, b) a chromogenic substrate for color readout 
(chlorophenol-red--D-galactopyranside, CPRG), and c) a cationic gold nanoparticle that binds 
reversibly to -Gal, inhibiting the enzyme (Figure 1a). The anionic surface of analyte bacteria 
introduces competitive binding between NP--Gal  and NP-bacteria,22 displaceing the -Gal with 
concomitant restoration of activity. The released and active enzyme converts the pale yellow 
substrate into the red product, providing a colorimetric readout (Figure 2.1). Part of these results 
have been published in the Journal of the American Chemical Society (2011, 133, 9650-9653).
23
 
 
Figure 2.1. Schematic illustration of the enzyme-amplified sensing of bacteria, showing the 
relative sizes of 2 nm core diameter particles and β-Gal. 
2.2 Results and Discussions 
Prior to sensing studies, we conducted activity titrations of -Gal-catalyzed hydrolysis of 
the CPRG substrate using different functionalized NPs, NP1-NP4 (Figure 2.2). The purpose of 
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these studies is to screen the best candidate that inhibits enzyme activity most and binds to 
bacterial cell surface most as well. 
 
Figure 2.2. Molecular structure of ligands on the selected cationic functionalized gold 
nanoparticles.  
 
Figure 2.3.  Inhibition of activity assay of β-Gal (0.5 nM) with 5 mM substrate CPRG upon 
addition of NP1-NP4. 
The titration studies were performed at 0.5 nM of -Gal, a concentration that provided a 
reasonable time course (~10 min) for the colorimetric event. The normalized first-order rate of 
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chromogenic substrate (CPRG, max = 595 nm) hydrolysis was plotted versus the molar ratio of 
nanoparticles to -Gal, and decreased upon addition of nanoparticles, and this trend was similar 
for all four cationic AuNPs (Figure 2.3). The decrease hydrolysis rate proved that interactions 
between enzyme and NPs resulted in inhibition of enzymatic reaction. As a control, the enzyme 
inhibition was also studied with neutral tetraethylene glycol (NPTEG) and carboxylate (NPCO2) 
functionalized nanoparticles, with no inhibition observed with these particles, indicating the 
interaction between enzyme and cationic AuNPs was mainly electrostatic interaction. The 
concentrations at which the enzyme was completely inhibited differed for different NPs. For 
example, NP1 and NP2 inhibited the enzyme completely at 5.95 nM while it was 23.5 nM for 
NP3 and 3.75 nM for NP4. We assumed that the various inhibiting rate and concentration result 
from the difference in NP-enzyme binding affinity. The similar inhibiting capability of NP1 with 
a hexyl-end group and NP2 with a cyclo-hexyl-end group indicated that similar carbon chain 
length end groups possess similar interaction affinity to the enzyme, and NP1’s hexyl group was 
mostly like folded, making it behave more similarly to NP2. The presence of an aromatic group, 
however, decreased interaction affinity with the enzyme. 
 
Figure 2.4. Inhibition of β-Gal before (“ON”) and after (“OFF”) addition of NP2. And the “OFF” 
state is the concentration chosen to construct the colorimetric biosensor. 
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 After preliminary activity studies, NP2 was chosen as the best candidate, (Figure 2.3), 
inhibiting the -Gal activity at very low concentrations as well as restoring the -Gal activity 
when interacted with bacteria. The sensor was constructed with NP2 concentration that gave 
“OFF” activity state of the enzyme (Figure 2.4). The best performance from NP2 was proposed to 
be a balance of binding affinities towards both the enzyme and bacterial cells. 
 
Figure 2.5. Limit of detection of E. coli using -Gal/NP2 nanocomposite. Kinetic absorbance 
response upon addition of different bacteria concentrations, as control -Gal/NP2 nanocomposite 
was used without bacteria.  At the top, microplate wells showing the color change upon variation 
of bacteria concentrations. 
For our initial sensing studies, E. coli was employed as a model analyte (Figure 2.5). 
Solutions containing different bacteria concentrations were used to investigate the limit of 
detection (LOD) of this sensing system. From these studies, we can reproducibly differentiate 
bacterial levels as low as 100 cfu/mL (three replicates were carried out for each sample). Each 
concentration can be discerned not only by intensity curves and the Vmax histogram but also by 
visible color changes: images taken immediately after reading (10 min) by an LCD camera 
demonstrate this colorimetric effect (Figure 2.5 top). 
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I next investigated the application of our design to a test strip format suitable for potential 
portable use,
24
 featuring visual read-out of the originated color in comparison to a reference color 
scale.
25
 A key issue in this format is how to generate rapid and reproducible response times. 
Rapid bacterial penetration occurs on highly porous papers, while restriction of particle/enzyme 
conjugates to the surface occurs on less porous materials. Considering these issues, a wide range 
of materials available were explored to maintain the enzyme activity, the efficiency of enzyme 
inhibition, and activity recovery process. Of the materials tested, GF/B binder-free microfiber 
filter (Whatman, cat. No. 1821021) was selected as the ideal platform due to its high wet strength, 
high loading capacity and rapid response.  
 
Figure 2.6. Enzymatic inhibition-colorimetric assay of β-Gal (15 nM) against 25 mM substrate 
CPRG upon addition of cationic, anionic and neutral nanoparticles. a. carboxylate (NPCO2), b. 
hydroxyl (NPTEG), and c. quaternary amine functionalized gold nanoparticles on a platform 
testing. Inset shows total inhibition for the positive nanoparticle NP2 at 80 nM, while no 
inhibition was observed for both the anionic and neutral AuNPs even at 160 nM. 
The formulation of the strip sensor featured 25 mM CPRG and 15 nM β-Gal, providing 
conversion from yellow to dark red within 10 minutes with uninhibited enzyme. Due to the 
difference in reaction rates in aqueous solution and on paper format, inhibition studies were 
carried out again to determine the optimal concentration of cationic particle NP2 and β-Gal to 
form the hybrid enzymatic nanocomposite sensor [(β-Gal/NP2) complex]. NPTEG and NPCO2 
were also used as controls with no inhibition observed (Figure 2.6). The β-Gal/NP2 complex was 
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ultimately generated by mixing β-Gal (15 nM) and NP2 (80 nM) and allowing the composite to 
dry for 15 minutes. 
To test the performance of our system on a paper strip, 3 L of CPRG (25 mM), complex 
solution and solutions from 1108 to 1104 cfu/mL of E. coli were spotted onto GF/B filter paper. 
Images were obtained after 10 min with an LCD digital camera and appropriate lighting. As 
shown in Figure 5, clear visual differences were observed for concentrations ranging from 10
8
-
10
4
 cfu/mL. To provide quantitative assessment of the test strips, the RGB profile of the images 
were analyzed. The plots of RGB colorimetric channels (all values were taken at least three times) 
in Figure 2.7 established the effectiveness of the chromogenic platform, demonstrating that 1×10
4
 
cfu/mL can be distinguished using this method. 
 
Figure 2.7. Schematic illustration of the RGB colorimetric analysis to monitor color changes on 
the GF/B filter paper spot at pH 7.4. a. image of the enzymatic activity response-colorimetric 
assay of the β-Gal-NP2 complex upon addition of E. coli at different concentration, CPRG 
substrate was used as a control. b. red, green, and blue channels obtained from the original 
sample a to differentiate between bacteria concentration. c. the extracted values of red, green, and 
blue channel from the original data a. This process is repeated three times for each measurement 
in a series of images. 
For field application, implementation of enzymatic amplified test strips is challenging. 
Both enzyme and enzyme substrate should be incorporated on the same strip for simple and direct 
detection purpose. But contact of these two elements should be prevented during fabrication 
process to avoid pre-test reaction. Therefore, we investigated the possibility of using inkjet 
printing technique for fabrication of this enzyme-NP hybrid sensor. In the fabrication process, the 
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enzyme and NPs were pre-mixed in water (50 nM β-Gal and 500 nM nanoparticles) and put into a 
clean unused inkjet cartridge. And the colorimetric enzyme substrate CPRG solution in water (2.5 
mM CPRG) was put into another clean unused inkjet cartridge. Utilizing the inkjet printers 
CMYK color model, four separate printing channels are available and here we used two channels 
for sensor fabrication.  
 
Figure 2.8. Schematic illustration of inkjet printing of the NP-based enzymatic amplified bacteria 
test strips. Inks were printing in a checker pattern to ensure no interaction before use. 
As illustrated in Figure 2.8, the enzyme-NP conjugate solution was represented by the 
black (key) ink, and the solution was dispersed onto the paper from the key channel. The enzyme 
substrate, CPRG solution, as represented by the yellow ink, was casted onto the paper from the 
yellow channel. The printing was done in such separation manner in order to avoid interactions 
between the materials before use. After immersed in water, if the water is clean without bacteria, 
enzyme remains restricted by NP and the strip shows a light yellow color, whereas if the water is 
contaminated by bacteria, enzyme is replace by bacteria and mixes and interacts with the 
substrate for reaction, giving out a red to purple color depending on the actual bacteria 
concentration in the sample. 
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For fabrication of these strip sensors, the activity of β-Gal after printing process was 
tested first. And the result confirmed that β-Gal survived the printing process and reserved its 
activity. The sensor strips were then printed, cut, and tested with solutions containing different 
E.coli bacteria concentrations. These strips turned purple upon immersion in the bacteria 
containing solution (Figure 2.9) and the limit of detection was demonstrated by the photos as 10
2
 
cfu/mL. The increased sensitivity on the strips compared to spotted filter paper format could 
result from the more uniform dispersion of the enzyme-NP conjugates and substrate solutions. 
Besides in the case of the spotted filter paper, more materials could penetration inside the filter 
paper, whereas the printing process shortens the drying time and creates a thin film on top of the 
paper, preserving more materials on the surface for interaction and detection.   
 
Figure 2.9. Sensitivity of the colorimetric sensor printed by an inkjet printer. The unit of the 
concentrations above the strips is cfu/mL.  
2.3 Conclusions 
In this work, enzyme-nanoparticle assemblies have been used to provide rapid and 
sensitive colorimetric sensing of bacteria. The use of enzyme enabled not only signal 
amplification but also colorimetric readout generation, allowing future application for portable 
devices. Using this system in a solution platform, bacteria concentrations as low as 100 cfu/mL 
could be determined in a matter of minutes. Transfer of this methodology to a test strip format 
provided a potential tool for field applications with a visual sensitivity of 10
4
 cfu/mL. The 
selective instead of specific detection principle adapted in this system provides a great potential 
for detection of total bacterial count in water sample, which is an important factor considered for 
water quality. Finally, the feasibility of this system was demonstrated by inkjet printing technique. 
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Test strips composed of this enzyme-nanoparticle hybrid colorimetric bacteria sensor were 
printed by an inkjet printer. Success in this work and the inkjet printing work confirmed that 
nanoparticles are great candidates for rapid and sensitive detection of bacteria. 
The rapid detection (within 15 minutes) and visual readout provided by the studies 
revealed here can enable real-time bacteria detection, which is critical for determination of water 
quality, potentially preventing many people from getting ill by drinking or swimming in 
contaminated water. Besides, the high sensitivity showed a great potential to match certain 
detection standard level. The easy and fast fabrication demonstrated by the inkjet printing 
technique suggests a great commercialization potential. All together, our studies not only showed 
that nanoparticles offer a great platform for bacteria detection, but also present a system that 
could be manufactured in mass production and used for on-site real time bacteria detection.  
2.4 Experimental methods 
Synthesis of AuNPs 1-4  Pentanethiol-coated AuNPs with core diameter 2 nm were 
synthesized using the Brust-Schiffrin two-phase synthesis method.
26
 Murray place-exchange 
method
27
 was used to obtain the quaternary ammonium functionalized AuNPs 1-4.  The cationic 
AuNPs were very stable in aqueous solution. 
Activity assays -galactosidase (-Gal) and the colorgenic substrate chlorophenol-red--
D-galactopyranside, CPRG were purchased from Sigma-Aldrich. In this study, nanoparticle and 
-Gal solutions were prepared in sodium phosphate buffer solution (5 mM, pH 7.4).  In the 
activity assay studies, -Gal (0.5 nM) was incubated with various concentrations of NP1-NP4 for 
30 minutes and 1.5 mM of the colorgenic substrate (CPRG) was added. As control experiments, 
the enzymatic activity of -Gal was also monitored in the presence of neutral tetraethylene glycol 
and carboxylate functionalized nanoparticles as well as an enzymatic protein (-Gal). The -Gal 
stock concentration was 314 nM, while the stock concentrations of NP1-NP4 were prepared at 
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100 nM. The inhibition studies in solution were carried out at pre-determined times by adding 5 
L of CPRG (1.5 mM in PB buffer) and 5 L of PB buffer into 200 L -Gal/AuNP solution.  
The enzymatic activity was followed by monitoring product formation every 22 s for 15 minutes 
at 595 nm using a microplate reader (SpetraMax, Molecular Devices). The samples were 
measured in triplicates. From the activity/inhibition studies, optimal concentrations of -
Gal/AuNP complexes were obtained. Once the different inhibiting characteristics of the -
Gal/AuNP complexes were established, stoichiometric amounts of -Gal and NP1-NP4 were 
used to the bacteria detection.  
In the case of the test strip platform, 25 mM CPRG and 15 nM β-Gal was set up in a way 
to make the reaction take place at an appropriate speed for tuning the color of the substrate from 
yellow to dark red within a pre-determined time i.e. 10 minutes. Once the different inhibiting 
characteristics of the -Gal/NP2 complexes were established, stoichiometric amounts of -Gal 
and NP2 was used on the bacteria detection. NPTEG and NPCO2 were also used, as control 
experiment and no inhibition was observed as expected. The samples were measured in triplicate. 
Bacterial culture E. coli was inoculated in LB broth and incubated over night at 37 °C 
till stationary phase. The overnight culture was then centrifuged and washed with 5 mM 
phosphate buffer (pH 7.4) for three times. Bacteria were resuspended in 5 mM phosphate buffer 
and the concentration was determined by measurement of optical density at 600 nm (OD600). 
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CHAPTER 3 
ARTIFICIAL ENZYME MIMIC-BASED COLORIMETRIC SENSOR 
3.1 Introduction 
Detection of bacteria requires development of fast, sensitive, and cost-effective sensors 
aimed at point-of-care applications.  Among these sensors, colorimetric methods provide both 
enhanced instrumental transduction as well as the potential for direct visual readout.
1 
For example, 
the clearly distinguished color shifts resulting from controllable aggregation of gold nanoparticles 
have facilitated simple color readout for biosensor applications.
2
  
Array-based sensing uses differential binding interactions with an array of selective 
receptors, providing an alternative to biomarker detection
3
.
 
 This alternative is based on the 
mammalian olfaction and gestation process, utilizing sensors biased toward classes of analytes. In 
this approach, an array composed of selective rather than specific receptors that bind to analytes 
by different binding characteristics. This cross-reactive sensor array is composed of multiple 
sensors, most of which respond to each analyte, but generating a level of variance. This variance 
produced by each sensor element results in a fingerprint pattern corresponding to each analyte, 
serving as guidance for identification of these analytes. 
Colorimetric implementation of the array-based sensing methodology has created highly 
effective small molecule sensors that have been applied to a variety of important analytes.
4
 
Application of colorimetric methods to array-based sensing of bacteria is challenging, however, 
due to the low concentrations of these materials relative to the amount of signal required for 
colorimetric transduction. In recent studies we have used enzyme amplification for colorimetric 
detection of bacteria.
5
 While enzyme-based amplification processes are attractive, the protein 
nature of enzyme stability under transport and storage conditions may limit the application of this 
strategy to highly controlled environments.
6
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Synthetic enzyme mimics
7
 such as macromolecular complexes,
8
 iron oxide 
nanoparticles,
9
 and cerium oxide nanoparticles
10,11
 feature higher stability than enzymes over a 
wide range of pH levels and temperatures. The ability of these mimics to catalytically amplify 
responses has made them useful for biosensing. For instance, Fe3O4 NPs that mimic horseradish 
peroxidase (HRP) activity have been used to replace HRP in traditional immunoassay techniques
9, 
12 
and to achieve label-free detection of nucleic acids.
13
  
In this chapter, I investigate the potential of artificial enzyme mimic, Fe3O4 NPs, to 
replace natural protein enzyme for colorimetric amplification biosensing. Due to the NP nature, I 
propose that Fe3O4 NPs can serve as both recognition and transduction elements, which will 
simply the fabrication of biosensor. First, I investigate if Fe3O4 NPs can be used for amplified 
colorimetric sensing using proteins as model analytes. The size, charge, and structure variation of 
different proteins serve as an excellent test bed, providing insights into the sensor principle and 
sensitivity.  I then further test if Fe3O4 NPs can be used for colorimetric detection of bacteria and 
the possibility of constructing test strips with these NPs. Part of these results have been published 
in the journal Small (2012, 8, 3589-3592)
14
. 
3.2 Results and discussion 
 
Figure 3.1. a. Structures of Dop-Fe3O4 and TMA-Fe3O4. b. Hydrodynamic diameter and zeta 
potential of Fe3O4 NPs in 5 mM CH3COONa buffer at pH 5.0. 
For our sensing studies, two NPs, dopamine functionalized Fe3O4 NP (Dop-Fe3O4 NP) 
and trimethylammonium functionalized Fe3O4 NP (TMA-Fe3O4 NP) were fabricated (Figure 3.1). 
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The different surface functionalization is designed to provide differential interactions to analytes. 
The hydrodynamic diameter and charges were listed in Figure 3.1 as well. Both NPs displayed 
positive charge when measure in sodium acetate buffer at pH 5.0.  TMA-Fe3O4 NP possesses a 
larger diameter due to the longer surface ligand compared to Dop-Fe3O4 NP.  
 
Figure 3.2. Schematic illustration of the Fe3O4 NP enzyme mimetic amplified colorimetric 
sensing of proteins.  
The sensing principle originates from the catalytic property of Fe3O4 NP, which mimics 
the HRP activity. In general, similar to HRP, Fe3O4 NP can catalyze oxidation of colorless 2,2'-
azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS), generating a green product in the 
presence of hydrogen peroxide (H2O2). In the presence of analytes, in this case, model analyte – 
protein, I propose there could be three possibilities. As illustrated in Figure 3.2, one possibility is 
when analyte, protein 1, has no interaction with Fe3O4 NPs, therefore the catalytic reaction occur 
without impact, yielding the dark green color in solution; another possibility is when analyte, 
protein 2, has moderate interaction with Fe3O4 NP and attaches on NP surface, leading to partial 
coverage of NP surface, and hence, to some extent blocks the access of substrate, ABTS, to the 
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NP core where the oxidation reaction is catalyzed, resulting to partial inhibition of NP catalytic 
activity and a lighter green color in solution; the third possibility is when analyte, protein 3, has 
strong interaction with Fe3O4 NP and forms protein-NP conjugate aggregation, in which case, the 
access to the NP is entirely blocked and NP catalytic activity is completely inhibited, giving a 
colorless solution. According to this hypothesis, analyte profile generation with these particles 
arises from differential interactions of these particles with analyte proteins with concomitant 
alteration in catalytic efficiency. 
 
Figure 3.3. Normalized OD at 420 nm upon protein addition with fixed NPs concentration (25 
µg/mL). a. Concentration dependent OD curve of lipase. b. Normalized OD curve of lysozyme 
with modest permutation. Results are average of three measurements and error bars are standard 
deviation. 
Initial studies focused on optimizing the sensor response. An effective chromogenic 
response was observed using 25 µg/mL Fe3O4 NP with 2.5 mM H2O2 and 1 mM ABTS in 5 mM 
sodium acetate (CH3COONa) buffer (pH 5.0). Changes in NP activity were then determined 
using two model proteins, lipase and lysozyme. With NP concentration fixed and protein 
solutions varied, NP activity titration studies were carried out by monitoring the absorption of the 
oxidized product at 420 nm.  In the case of lipase, a dramatic drop in reaction rate was observed, 
with complete inhibition observed at higher concentrations (50 nM, Figure 3.3 a), indicating that 
lipase was able to affect NP’s catalytic activity in a concentration-dependent manner and was able 
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to completely prevent the colorimetric reaction from taking place, which fitted the third proposed 
case of analyte-NP interactions where analytes display strong interaction towards NPs. By 
contrast, lysozyme did not significantly affect the colorimetric reaction up to a concentration of 
100 nM (Figure 3.3 b), indicating that lysozyme was not able to affect NP’s catalytic activity, 
which matched the first proposed case of analyte-NP interactions where analytes do not exhibit 
binding affinity towards NPs. 
 
Figure 3.4. Hydrodynamic diameters of a. lipase, functionalized Fe3O4 NP, and lipase-NP 
complex, and b. lysozyme, functionalized Fe3O4 NP, lysozyme-NP complex. Results are average 
of three measurements and error bars are standard deviation. The NP concentration used in the 
size measurement is 250 µg/mL and the protein is at a concentration of 500 nM. 
The different behaviors towards NP catalytic activity observed above can be used to 
differentiate the two proteins. The mechanism for this protein differentiation was probed by 
dynamic light scattering (DLS) measurements of the protein-NP complexes. For the DLS studies, 
10-fold higher concentrations of particle and protein were used to provide reliable DLS signals. 
According to the size measurements from DLS, Lipase-NP complexes formed large aggregates 
with both Dop-Fe3O4 NP and TMA-Fe3O4 NPs (Figure 3.4 a), consistent with the large change in 
activity observed. In contrast, no significant changes in particle size were observed after 
incubation with lysozyme (Figure 3.4 b), consistent with the modest permutation in activity 
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observed. The NP activity titration studies and the DLS experiments supported the two extreme 
cases, complete inhibition and no inhibition, in the initial hypothesis. 
Sensing of individual analytes in isolation provides a testbed for array-based sensors, 
providing insight into their ability to detect small changes in analyte structure and property. The 
ability of our sensor to discriminate proteins was tested using ten proteins featuring varying size 
and charge (Table 3.1). In the procedure, each protein solution was first mixed with NP (25 
µg/mL) to a final protein concentration of 50 nM and incubated at room temperature for 30 
minutes. This was followed by the addition of H2O2 (2.5 mM) and ABTS (1 mM) into each 
solution. After 15 minutes of incubation at room temperature, OD responses (OD/OD0, where 
OD0 is a control without addition of protein) at 420 nm were monitored. 
Table 3.1. Physical properties of analyte proteins. 
Protein 
MW 
(kDa) 
pI 
   α-amylase (α-Am) 50 5.0 
   bovine serum albumin (BSA) 66.3 4.8 
   α-chymotrypsin (ChT) 25 8.7 
   cytochrome c (CytC) 12.3 10.7 
   transferrin (Tf) 76 5.9 
   human serum albumin (HSA) 69.4 5.2 
   lipase (Lip) 58 5.6 
   lysozyme (Lys) 14.4 11.0 
   myoglobin (Myo) 17 7.2 
   alkaline phosphatase (PhosB) 140 5.7 
 
As displayed in Figure 3.5 b, the two particle sensor array generated a range of outputs.
15
 
As a general trend, proteins possessing lower pIs (α-Am, BSA, HSA, Lip) exhibited relatively 
stronger inhibition of the NP activity than those with higher pIs (Lys, CytC, ChT, Myo), 
indicating surface charge plays an important role in discrimination. Proteins with similar pIs such 
as Lip (pI 5.6) and PhosB (pI 5.7), also gave different signal patterns, however, indicating that 
protein size also plays a role in protein-NP interactions. The sensor was even able to distinguish 
BSA and HSA, two very similar proteins with close pI and size, showing that protein surface 
functionality, hydrophobicity for example, is also a factor in the detection process. Comparison 
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between these protein pairs revealed that this two-NP sensor array detects analyte protein based 
on charge, size, and surface functionality, differentiating analytes from many physical and 
chemical properties. Each protein can be reproducibly discerned by the OD response patterns. 
The pattern differences among analytes can be easily detected even by the naked eye (Figure 3.5 
a).  
 
Figure 3.5. Array-based sensing of ten proteins. a. Photograph of the color change upon addition 
of protein solutions at 50 nM. b. OD response (OD/OD0 at 420 nm) patterns in the presence of 
proteins at 50 nM (responses are an average of five measurements and the error bars are the 
standard deviation). c. Canonical score plot for the OD response patterns as obtained from LDA 
with 95% confidence ellipses. 
Linear discriminant analysis (LDA) was employed to quantitatively differentiate the OD 
response patterns of the Fe3O4 NPs with proteins. All five replicates of the ten proteins are 
grouped with 100% accuracy according to the jackknifed classification matrix, and scores of the 
two factors are plotted with 95% confidence ellipses (Figure 3.5 c). In the canonical score plot, 
the distribution of analyte clusters along the factor 1 axis primarily reflects the OD/OD0 value. 
And proteins with lower pIs were primarily located on the left side of the plot, below value of 0, 
while proteins with higher pIs clustered mostly on the right side of the plot. In the LDA score plot, 
six replicates from each sample were closely overlapped with each other, indicating the sensor 
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works in a precise manner, which is an important attribute for biosensor development. The 
individual response from each of the elements provides reasonable differentiation: TMA-Fe3O4 
NP itself can differentiate the ten proteins with 90% accuracy and Dop-Fe3O4 NP with 78%. This 
result also demonstrated that necessity of using both NP to compose an array to improve 
sensitivity. It is noteworthy that by the use of only two modified Fe3O4 NPs, the sensor can detect 
and identify ten proteins rapidly and effectively.  
The detection efficiency was further validated by the identification of unknown samples. 
80 protein samples were generated and randomly assigned with a number by one person. The OD 
response of each sample was collected by another person and put into the training set shown in 
Figure 3.5 c for classification and identification.  The blind tests outcome was then verified with 
the person who prepared the samples. The results were displayed in Table 3.2, 76 out of 80 
unknown samples were correctly identified, giving 95% accuracy, which showed that the sensor’s 
performance was not only precise but also accurate. 
Table 3.2. Identifiation of 80 unknown protein samples with LDA using Fe3O4 NP sensor array. 
Entry 
Absorbance response pattern (OD/OD0) Identification Accuracy 
Dop-NP TMA-NP Proteins YES/NO 
1 0.211908 0.399919 α-Am Yes 
2 0.479546 0.621516 HSA Yes 
3 0.462776 0.318205 BSA Yes 
4 0.94571 1.057261 Lys Yes 
5 0.916518 1.255711 CytC Yes 
6 0.926287 1.357754 CytC NO 
7 0.899918 1.056053 ChT Yes 
8 0.541769 0.437557 PhosB Yes 
9 0.075944 0.17772 Lip Yes 
10 0.711499 0.872295 Tf Yes 
11 0.547641 0.429305 PhosB Yes 
12 0.893312 1.037939 ChT Yes 
13 0.912566 0.843313 Myo Yes 
14 0.697439 0.909731 Tf Yes 
15 0.221394 0.390661 α-Am Yes 
16 0.477796 0.633592 HSA Yes 
17 0.967675 1.047197 Lys Yes 
18 0.458824 0.32545 BSA Yes 
19 0.952429 1.281071 CytC Yes 
20 0.07871 0.174298 Lip Yes 
21 0.965134 1.35715 CytC Yes 
22 0.081025 0.172688 Lip Yes 
23 0.465938 0.368723 BSA Yes 
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24 0.526919 0.430311 PhosB Yes 
25 0.882245 1.013988 ChT Yes 
26 0.683832 0.873302 Tf Yes 
27 0.210779 0.400523 α-Am Yes 
28 0.456396 0.612458 HSA Yes 
29 0.855368 0.824796 Myo Yes 
30 0.928489 1.041763 ChT NO 
31 0.704328 0.870484 Tf Yes 
32 0.969651 0.96991 Lys Yes 
33 0.470286 0.629365 HSA Yes 
34 0.864741 1.030291 ChT Yes 
35 0.910251 1.273624 CytC Yes 
36 0.468253 0.336118 BSA Yes 
37 0.900031 0.889001 Myo Yes 
38 0.077638 0.170675 Lip Yes 
39 0.206601 0.384019 α-Am Yes 
40 0.52387 0.415618 PhosB Yes 
41 0.20677 0.391668 α-Am Yes 
42 0.917365 0.855791 Myo Yes 
43 0.078202 0.171279 Lip Yes 
44 0.702747 0.853779 Tf Yes 
45 0.950566 1.019221 Lys Yes 
46 0.434996 0.629365 HSA Yes 
47 0.94108 1.252893 CytC Yes 
48 0.494678 0.410989 BSA NO 
49 0.463002 0.378585 BSA Yes 
50 0.863273 1.00473 ChT Yes 
51 0.076452 0.174499 Lip Yes 
52 0.937579 1.038945 Lys Yes 
53 0.21044 0.373956 α-Am Yes 
54 0.525959 0.414612 PhosB Yes 
55 0.453347 0.358861 BSA Yes 
56 0.887948 1.011975 ChT Yes 
57 0.914655 0.821978 Myo Yes 
58 0.669603 0.845728 Tf Yes 
59 0.914768 1.245245 CytC Yes 
60 0.460405 0.613264 HSA Yes 
61 0.480845 0.60642 HSA Yes 
62 0.410491 0.312569 BSA Yes 
63 0.911154 0.854986 Myo Yes 
64 0.678863 0.853578 Tf Yes 
65 0.886367 0.988427 ChT Yes 
66 0.516586 0.41582 PhosB Yes 
67 0.20502 0.378183 α-Am Yes 
68 0.072217 0.168663 Lip Yes 
69 0.92352 1.033712 ChT NO 
70 0.921882 1.243232 CytC Yes 
71 0.994608 1.264366 CytC Yes 
72 0.859603 0.838281 Myo Yes 
73 0.209537 0.380396 α-Am Yes 
74 0.477739 0.618698 HSA Yes 
75 0.919455 1.038744 ChT Yes 
76 0.073911 0.177921 Lip Yes 
77 0.542672 0.429707 PhosB Yes 
78 0.460405 0.364698 BSA Yes 
79 0.677451 0.852571 Tf Yes 
 40 
 
80 0.946049 1.073563 Lys Yes 
 
The initial experiments showed success of using Fe3O4 NPs for colorimetric sensing, and 
the amplification efficiency was demonstrated by the high sensitivity of differentiation ten 
proteins at 50 nM concentration. We were then interested to know if the artificial enzyme, Fe3O4 
NPs, can be used for detection of bacteria. The sensing principle remains the same for analyte 
bacteria with analyte proteins. Considering the real-world application, the fact that the sensor 
would remain colorless when tested with sample containing high bacteria concentration might 
bring confusion to users, we decided replace the substrate ABTS with pyrogallol, which changes 
color from light yellow to red upon reaction. In this way, sensor remains yellow when tested with 
high bacteria concentrations. One NP, Dop-Fe3O4 NP, was first tested with bacteria E. coli at 
different concentrations to explore the limit of detection. As shown in Figure 3.6, Dop-Fe3O4 NP 
catalytic activity was inhibited at high bacteria concentrations, and solutions remained light 
yellow, meanwhile NP activity was not affected at low bacteria concentrations, and solutions 
turned into red color after a few minutes. The difference of the clear color in response was 
evident from the red color of the standard reference (uninhibited conditions), providing readouts 
that can be easily interpreted visually. The limit of detection using Dop-Fe3O4 NP alone was 10
5
 
cfu/mL. This resuls indicated that synthetic Fe3O4 NPs could be indeed used for amplified 
colorimetric detection of bacteria. 
 
Figure 3.6. Sensitivity of the Fe3O4 NP colorimetric in solution. The unit of the concentrations 
above the strips is cfu/mL. 
Effective implementation of our sensing strategy requires higher throughput fabrication 
of substrates to realize a low cost of production. Likewise, accurate printing of both the 
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colorimetric substrate and nanoparticle must be done quickly and accurately. To provide the 
reagent H2O2 in reaction, we will first explore urea hydrogen peroxide (UHP, CH6N2O3), a widely 
available and stable chemical when stored cool and dry,
16
 as peroxide generator. In our sensor 
design, NPs were spatially deposited next to the colorimetric substrates and the peroxide 
generator (Figure 3.7). This process assured that all elements were intact without interaction. 
Upon immersion into the water sample, the substrate and peroxide were carried over the Fe3O4 
NPs, allowing oxidation to give color readout. In the presence of bacteria, however, Fe3O4 NP-
catalyzed reaction will be modulated, giving a lighter yellow color depending on the bacteria 
concentration. 
 
Figure 3.7. Schematic illustration of Fe3O4 NP-based inkjet printed test strip fabrication. 
Strips were then printed with Fe3O4 NPs, substrate pyrogallol, and urea hydrogen 
peroxide and these strips were tested with E. coli bacteria with different concentrations to probe 
the limit of detection. Photos of tested strips showed a sensitivity of 10
5
 cfu/mL (Figure 3.8), 
which was similar to the limit of detection obtained in sensing in aqueous solution. The dark 
brown color showed on strips was different from the red color in solution due to the solid state of 
substrate product. 
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Figure 3.8. Inkjet printed test strip sensitivity against E. coli. The unit of concentrations above 
strips is cfu/mL. 
The implementation of artificial enzyme mimic Fe3O4 NP in biosensor can potentially 
improve the stability as well as reduce cost. With an initial estimate of materials, labor, and 
machinery, it cost around only 42 cents per strip/test. The stability of these inkjet printed strip lies 
in two possible portions, including receptor/amplifier and the oxidant H2O2 source. Using 
synthetic enzyme mimic helped to increase stability of the receptor/amplifier, however, the 
robustness related to H2O2 source needs to be tested at different conditions such as different 
temperatures and pHs. The urea hydrogen peroxide can be further stabilized by addition of 
stabilizer such as NaH2PO4 or Na2H2P2O7 and a coating layer to prevent the release of H2O2 in 
moist conditions.
 
If urea hydrogen peroxide still cannot serve as a stable peroxide generator, more 
expensive hydrogen peroxide/polymer
17
 or UHP/polymer complexes
18
 could also be used that are 
more stable to decomposition.   
The sensitivity of current system, however, is not high enough to reach environmental 
quality cutoff. In ongoing and future work which is conducted by my colleagues, plans have been 
made to further optimize and improve the sensitivity by altering the NP surface ligand. The 
chemical functionality of these ligands can provide various binding profiles towards analytes and 
therefore can regulate the sensitivity of the system as seen in our previous work. We also believe 
that adjusting the Fe3O4 NP size can change the volume ratio of NPs to bacteria cells, and this 
change will affect the capability of bacteria to shield substrates from the nanoparticle surface, 
consequently modifying the sensitivity. 
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3.3 Conclusions 
In summary, a new platform has been developed for sensitive, fast, and effective 
colorimetric biosensor that uses a catalytically active particle for both recognition and signal 
transduction/amplification. By tuning the surface functionalities, The Fe3O4 NPs were able to 
differentiate ten proteins at a concentration of 50 nM, substantially lower concentrations than 
prior array-based protein sensors (1–350 µM). The robust nature of these synthetic enzyme 
mimics gives this strategy the potential to provide real-world sensors for both clinical and non-
clinical health applications. 
Further, I investigate with my colleagues the possibility of using the catalytic NP-based 
biosensor for detection of bacteria.  An iron oxide NP-composed test strip sensor was fabricated 
that gave color response upon bacteria as indication for water quality. This sensing system was 
integrated with inkjet printing approach to probe the feasibility of fast and precise fabrication of 
nano-sensors. The initial studies explored the sensitivity of the Fe3O4 NP based sensing system 
with model bacteria strains. The system was then transferred to a field friendly strip platform by 
inkjet printing strategy and was tested for bacteria detection in water. Data shown in this chapter 
demonstrated the successful proof-of-concept of this system. This system was also filed for patent 
for its great commercial potential. Our test strip-based colorimetric sensor can provide easy and 
rapid (within minutes) detection of bacteria in water without additional equipment. This type of 
technology has not been commercialized in current market. There should be a large market for 
our test strip, considering the breadth of the recreational water market segment as well as the 
desperate need for rapid detection of bacteria-contaminated drinking water in emerging nations. 
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3.4 Experimental methods 
Synthesis of dopamine functionalized Fe3O4 NP (Dop-Fe3O4 NP) Water-dispersible 
Dop-Fe3O4 NPs were synthesized and purified according to literature.
19
 In the general process, 
FeCl2•4H2O (99.4 mg, 0.5 mmol), FeCl3•6H2O (270.3 mg, 1mmol), and 20 g of diethylene glycol 
(DEG) were added to a nitrogen-protected three-necked flask. A solution of NaOH (160 mg, 4 
mmol) in 20 g DEG was then added to the flask. The mixture was heated for 2 h at 220 °C. At the 
end of heating, a mixture of 3-hydroxytyramine hydrochloride (189 mg, 1 mmol) in 400 μL of 
H2O and 5 g of DEG was injected into the flask. After cooling to room temperature (r.t.), the solid 
product was isolated by centrifugation and washed five times with ethanol and finally redispersed 
in water. 
Synthesis of dopamine trimethyl ammonium (DTMA) ligand 
Step 1. 
 
1-Bromoundecanoic acid (500 mg, 1.88 mmol) was dissolved in dry DCM. To this 
solution N-hydroxysuccinimide (216 mg, 1.88 mmol) was added followed by a solution of DCC 
(456 mg, 2.26 mmol) in 5 mL of dry DCM at 0 ºC. The mixture was stirred for 15 min, and then 
DMAP (46 mg, 0.38 mmol) was added. After 1 h the reaction was allowed to reach r.t.. A white 
precipitate formed indicating the advancement of the reaction. The reaction was continued for 24 
h. The white precipitate was filtered and the solvent was removed from the filtrate to give a 
residue that was then re-dissolved in DCM and washed with water. The organic layer was dried 
over Na2SO4, filtered and evaporated and the crude product obtained was purified by flash 
chromatography with 3:1 hexanes:EtOAc as eluent to give the activated acid in 90 % yield. 
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1
H NMR_(400 MHz, CDCl3): 1.24-1.42 (m, 12H, CH2); 1.56 (m, 2H, CH2); 1.77 (m, 2H, 
CH2); 2.25 (t, 2H, CH2); 2.72 (t, 4H, CH2); 3.31(t, 2H, CH2) 
Step 2. 
 
3-Hydroxytyramine hydrochloride (356mg, 1.88mmol) was dissolved in dry DMF and 
the solution was purged for 10 min with nitrogen gas. DIPEA (507mg, 3.76 mmol) was slowly 
added to the reaction mixture. The mixture was stirred for another 5 min and then compound A 
(670mg, 1.18 mmol) was added to the reaction mixture. The mixture was stirred at r.t. for 64 h. 
After that the DMF was evaporated under reduced pressure. The residue was dissolved in ethyl 
acetate. The soluble part was taken out and washed with 1M HCl and brine water. The organic 
component was dried over Na2SO4 and evaporated to get the crude product. The crude product 
obtained was purified by flash chromatography with 3:1 EtOAc:hexanes as eluent to give the 
activated acid in 55 % yield.
 
1
H NMR_(400 MHz, CDCl3): 1.24-1.42 (m, 12H, CH2); 1.56 (m, 2H, CH2); 1.81 (m, 2H, 
CH2); 2.18 (t, 2H, CH2); 2.65 (t, 2H, CH2); 3.31 (t, 2H, CH2); 3.55 (t, 2H, CH2); 6.42 (d, 1H, 
Harom); 6.66-6.74 (m, 2H, Harom) 
Step 3.  
 
Compound B (230 mg, 0.59 mmol) and trimethylamine (696 mg, 11.8 mmol) were 
dissolved in 1mL of EtOH. The solution was degassed with nitrogen gas. The reaction mixture 
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was stirred at r.t. for 64 h and then the solvent was evaporated under vacuum. The residue was 
purified by washing with hexane and ether several times to obtain C in 99% yield.  
1
H NMR_(400 MHz, MeOD): 1.24-1.42 (m, 12H, CH2); 1.56 (m, 2H, CH2); 1.81 (m, 2H, 
CH2); 2.18 (t, 2H, CH2); 2.78 (t, 2H, CH2); 3.19 (s, 9H, CH3); 3.31 (t, 2H, CH2); 3.55 (t, 2H, CH2); 
6.42 (d, 1H, Harom); 6.66-6.74 (m, 2H, Harom) 
Synthesis of trimethyl ammonium functionalized Fe3O4 NP (TMA-Fe3O4 NP) Sun’s 
method
20
 was used to obtain 4-nm Fe3O4 NPs. Fe(acac)3 (2 mmol) was mixed in phenyl ether (20 
mL) with 1,2-hexadecanediol (10 mmol), oleic acid (6 mmol), and oleylamine (6 mmol) under 
nitrogen and was heated to reflux for 30 min. After cooled to room temperature, the dark-brown 
mixture was treated with ethanol under air, and a dark-brown material was precipitated from the 
solution. The product was dissolved in hexane in the presence of oleic acid and oleylamine and 
reprecipitated with ethanol to give 4-nm Fe3O4 nanoparticles. A place-exchange reaction
21
 of 
DTMA dissolved in DCM with the obtained 4-nm Fe3O4 NPs was carried out for 2 days at 40 °C. 
DCM was then evaporated under reduced pressure. The residue was dissolved in a small amount 
of distilled water and dialyzed (membrane MWCO = 10,000) to remove excess ligands. 
Protein sensing Protein solutions were prepared freshly before use and concentrations 
were determined by UV absorbance at 280 nm and calculated using the theoretical extinction 
coefficient at 280nm (ε280). The extinction coefficients of different proteins are list in the table 
below. 
Table 3.3. Protein extinction coefficient. 
Protein 
ε280  
(M-1 cm-1) 
   α-amylase (α-Am) 130000 
   bovine serum albumin (BSA) 46860 
   α-chymotrypsin (ChT) 51000 
   cytochrome c (CytC) 23200 
   transferrin (Tf) 92300 
   human serum albumin (HSA) 37800 
   lipase (Lip) 54350 
   lysozyme (Lys) 38000 
   myoglobin (Myo) 13940 
   alkaline phosphatase (PhosB) 62780 
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Bacterial culture E. coli was inoculated in LB broth and incubated over night at 37 °C 
till stationary phase. The overnight culture was then centrifuged and washed with 5 mM 
phosphate buffer (pH 7.4) for three times. Bacteria were resuspended in 5 mM phosphate buffer 
and the concentration was determined by measurement of optical density at 600 nm (OD600). 
3.5 Supplementary information 
In our study, we found that hemoglobin had an enhancement in OD response instead of 
inhibition. We believe this is due to the peroxidatic activity of the heme group in hemoglobin (as 
noted in reference 15).  
 
Figure 3.S1. Normalized OD upon different hemoglobin concentrations with the fixed NPs 
concentration (25 µg/mL). OD curve of hemoglobin is concentration dependant in an increasing 
fashion till a saturated point. 
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Figure 3.S2. Normalized OD at 420 nm of Fe3O4 NPs (25 μg/mL), hemoglobin (50 nM), and 
hemoglobin-Fe3O4 NP complex. The catalytic activity of Hem-Fe3O4 NP complex is higher than 
that of Fe3O4 NPs but is lower than the sum of Fe3O4 NP and hemoglobin. 
 
Figure 3.S3. Photographs of color changes in the titration studies of lipase, lysozyme, and 
hemoglobin. Images were obtained by scanning right after reading OD at 420 nm. The 
peroxidase-like activity of both NPs (Dop- and TMA-Fe3O4) is inhibited by lipase and the green 
color intensity of the product from the catalyzed hydrolysis of substrate ABTS decreases as lipase 
concentration increases. The colorimetric signals have no significant differences in a wide range 
of lysozyme concentrations. The catalyzed colorimetric reaction rate is increased in the presence 
of hemoglobin, giving increased intensity of the green color in higher concentrations of 
hemoglobin. 
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CHAPTER 4 
MULTICHANNEL SENSOR FOR RAPID IDENTIFICATION OF BIOFILMS 
FORMED BY BOTH LABORATORY AND PATHOGENIC BACTERIA  
4.1 Introduction 
Biofilms on wounds, implants, and indwelling devices generate chronic and often life-
threatening infections and inflammation.
1
 These persistent infections can result in tissue damage, 
device dysfunction, implant failure, and even death.
 2, 3
 Biofilm infections are notoriously difficult 
to treat, as the biofilm matrix provides physical protection from antibiotic treatment, which is 
often enhanced by the presence of antibiotic resistant bacteria. Rapid detection and identification 
of biofilms can provide crucial information for early diagnosis and effective treatment,
 4
 however, 
the identification of bacterial species in biofilms is challenging due to their physiological 
heterogeneity.
 5
 Conventional biofilm detection methods rely on culturing, which requires several 
days for diagnosis and has low sensitivity.
 6, 7
 More recent, molecular detection methods, such as 
PCR
8
 and fluorescence in situ hybridization (FISH)
9
, have been developed based on genotyping 
and genomic profiling. While these approaches are rapid and have the potential for increased 
sensitivity, it remains challenging to efficiently detect and identify biofilms.
10 
  
The biofilm matrix accounts for over 90% of biofilm dry mass, providing a three-
dimensional microenvironment that protects the bacteria.
 11
 This architecture is a unique feature 
that defines biofilms, intimately regulating the physical and functional properties of the biofilm.
 12
 
Both the physical structure of the biofilm and the composition of the extracellular polymeric 
substances (EPS) in the matrix, such as polysaccharides, proteins, nucleic acids, and lipids, vary 
among bacteria species.
13
 For example, polysaccharides are neutral in Streptococcus,
14
 
polyanionic in Pseudomonas,
 15
 and polycationic in Staphylococcus.
16
 Within a species, the EPS 
are even diverse; polysaccharides from various strains of Streptococcus thermophilus feature 
different monomer compositions and ratios and possess different molecular masses.
 17
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Based on the structural and chemical differences between biofilms, we hypothesized that 
an array-based "chemical nose" approach could be used to detect and differentiate between 
species and even strains in a biofilm,
 18, 19, 20
 potentially minimizing the interference caused by 
biofilm heterogeneity
11
 and phenotypic diversity of bacteria.
 21, 22
 Array-based sensing has been 
used to identify species and strains of planktonic bacteria.
 23, 24
  Optical sensing of biofilms is 
however a much more challenging prospect due to the physical heterogeneity of the films, which 
introduces significant variability to the sensing process.  
 
Figure 4.1. Schematic illustration of the multichannel sensing. The sensor is composed with 
AuNP-fluorescent protein conjugates which will be disrupted in the presence of biofilms. The 
disruption turns on fluorescence and gives different colored fluorescence patterns for biofilm 
identification. 
In this chapter, I describe a gold nanoparticle (AuNP)-based multichannel fluorescence 
sensor to detect and identify the species composition of biofilms based on the overall biofilm 
physicochemical properties.  This sensor features AuNP-fluorescent protein conjugates that can 
be disrupted to give fluorescent readouts in the presence of bioflms (Figure 4.1), generating an 
essentially instantaneous readout.  The key feature of this sensor platform is that it uses a three-
color RGB output that generates a ratiometric response, which is less sensitive to sample 
variability,
 25, 26
 enabling us to completely differentiate bacterial species and strains of six biofilms, 
including two pathogenic clinical isolates, within minutes. The versatility of this sensor is further 
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demonstrated by discrimination between two bacterial species in a co-cultured biofilm-fibroblast 
cell wound model.
 27
 These results have been written in a manuscript ready for submission. 
4.2 Results and discussion 
We first fabricated two AuNPs (~2 nm core), one featuring a cationic hydrophobic (NP1) 
and the other a hydrophilic (NP2) functional group (Figure 4.2 a). Multi-channel output is 
provided through reversible adsorption followed by partial displacement of three fluorescent 
proteins with well-separated excitation and emission spectra (Figure 4.2 b):  red (tdTomato),
28
 
blue (EBFP2),
29
 and green (EGFP).
30
 These proteins feature negative surface charge, allowing 
electrostatic interactions with cationic NP1 and NP2. In the presence of biofilms, the 
fluorescently quenched
31
 AuNP-fluorescent protein conjugates are disrupted by the competitive 
interactions between the negatively charged EPS produced by the bacterial species and the 
cationic AuNPs, restoring the fluorescence, and hence generate discerning patterns for species 
recognition in the biofilm (Figure 4.1).  
 
Figure 4.2. a. Molecular structure of NP surface ligand. b. The absorption and emission spectra 
of the three fluorescent proteins. 
In the sensor design, NP1 and NP2 were chosen to afford selective hydrophobic and 
hydrophilic interactions with target biofilms. The presence of both NPs could offers competitive 
hydrophobic/hydrophilic interactions with biofilm EPS, maximizing biofilm species composition 
differences. We first studied the binding affinities of the fluorescent proteins towards the two 
AuNPs by fluorescence titration. In these studies, an equimolar mixture of the three fluorescent 
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proteins was titrated with NP1, NP2, and an equimolar mixture of NP1 and NP2 (Figure 4.3). In 
all cases, with increasing NP concentrations, fluorescence from the three proteins was efficiently 
quenched.  
 
Figure 4.3. a. The sensor elements and molecular structures of the functional ligands of NP1 and 
NP2. Fluorescence titration with b. NP1, c. NP2, d. an equal molar mixture of NP1 and NP2. 
Each value is an average of three replicates and the error bars are standard deviations. 
Nonlinear curve fitting was used to calculate the NP-protein complex stability constant 
(Ks) and association stoichiometry (n) (Table 4.1). The binding constant of tdTomato was 
significantly lower than EBFP2 and EGFP, indicating that the binding interaction of tdTomato to 
AuNPs was much weaker. A plausible explanation was that tdTomato is a tandom dimer and 
much larger than EBFP2 and EGFP in size, leading to its weaker binding interaction to AuNPs. 
These variations in FP-AuNP conjugate stabilities and the association stoichiometry promised the 
triple-channel sensing. To provide an effective dynamic range, we chose the point where the NP: 
fluorescent protein ratio was 0.8 (160 nM of total AuNPs and 200 nM of each fluorescent protein), 
generating efficient quenching of all three proteins. 
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Table 4.1. The binding parameters derived from the fitting of the fluorescence titration data. 
AuNP Protein Binding constant (Ks), M
-1
 Association stoichiometry (n) R
2
 
 
NP1 
EBFP2 (4.18±3.15)×10
8
 2.34±0.22 0.9822 
EGFP (8.03±2.09)×10
9
 1.68±0.08 0.9837 
tdTomato (5.52±5.24)×10
8
 0.89±0.03 0.9830 
 
NP2 
EBFP2 (1.54±1.10)×10
7
 6.86±3.34 0.9727 
EGFP (2.86±0.50)×10
8
 2.52±0.08 0.9938 
tdTomato (6.44±6.66)×10
6
 4.20±2.82 0.9948 
 
NP1+NP2 
EBFP2 (7.77±3.73)×10
7
 3.18±0.49 0.9856 
EGFP (7.86±2.43)×10
8
 2.08±0.06 0.9897 
tdTomato (3.31±2.62)×10
7
 1.88±0.41 0.9766 
 
After optimization of particle/protein concentrations, we tested the discriminatory power 
of our sensor against six bacterial strains representing 5 species (Amycolatopsis azurea, Bacillus 
licheniformic, Bacillus megaterium, Escherichia coli, Pseudomonas aeruginosa), including one 
clinical isolate of uropathogenic E. coli. and P. aeruginosa. The bacteria were cultured for three 
days in a 96-well microplate in modified LB media (see Materials and Method) at room 
temperature.
 32
 Biofilms were observed in each of the culture wells. The particle/protein sensor 
solution was then added to each well and incubated for 45 minutes before reading. As shown in 
Figure 4.4, the six bacteria biofilms displayed distinct response patterns. The two pathogenic 
bacteria, E. coli CD-3 and P. aeruginosa CD-1006 showed the lowest and the highest responses, 
respectively, in all three channels, and thus is clearly distinguished from biofilms formed by the 
remaining the laboratory strains. Interestingly, the biofilms of B. licheniformis and P. aeruginosa, 
species known to form strong biofilms,
 33, 34, 35
 exhibited higher sensor responses than biofilms of 
the other three species, indicating stronger interactions between the AuNPs and biofilms. 
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Figure 4.4. Detection and identification of biofilms formed by four laboratory strains and two 
uropathogenic strains. Triple-channel fluorescence response patterns in the presence of biofilms. 
I0 is the fluorescence intensity in the absence of biofilms. Each value is an average of six 
replicates and the error bars are standard deviations.  
Quantitative discrimination between the bacterial strains was obtained using linear 
discriminant analysis (LDA).
36
 According to the jackknifed classification matrix in the LDA,
 37
 
the six data groups each containing six points from each biofilm were classified and showed 100% 
separation. The canonical scores of the first two factors were plotted with 95% confidence 
ellipses in Figure 4.5, showing 100% discrimination between the biofilms of the six bacterial 
strains. Comparison between individual channels and the three channel system (Table 4.2) 
indicates that individual channels were incapable of complete classification, demonstrating the 
importance of multi-channel sensing in detecting complex analytes such as biofilms. The biofilm-
based clusters did not display Gram-stain related separation. This is presumably because the 
structural differences between Gram-positive and Gram-negative bacteria are located primarily in 
their cell walls, which may be masked by the biofilm EPS in which the bacteria are embedded.  
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Figure 4.5. Canonical score plot of the fluorescence response patterns as obtained by LDA 
against the six bacterial biofilms. 
 
Table 4.2. The jackknifed classification accuracy based on the parts of the triple-channel 
fluorescence (R: tdTomato, G: EGFP, and B: EBFP2). 
Channel Accuracy Channel Accuracy 
R 61% R+B 78% 
G 90% R+G 90% 
B 66% G+B 93% 
R+G+B 100%   
 
In addition to clustering, LDA is capable of identifying unknown samples once the 
system has been "trained" using a training set of analytes.
 38
 In practice, four cultures of each of 
the six bacterial strains were prepared and labeled randomly to generate a pool of 24 unknown 
biofilm samples. The sensor identified 23 out of 24 samples (96%) correctly (Table 4.3), 
simultaneously demonstrating the diagnostic possibilities of the sensor and the robustness of the 
clustering. 
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Table 4.3. Identification of 24 unknown biofilm samples. 
# I/I0 Identification Verification 
Blue Green Red 
1 4.151  1.734  1.119  A.azu A.azu 
2 12.435  4.817  1.370  B.mega B.mega 
3 1.485  1.088  1.134  CD-3 CD-3 
4 5.091  1.924  1.318  DH5α DH5α 
5 18.641  6.802  1.523  B.liche B.liche 
6 20.647  8.973  1.507  P.aeru P.aeru 
7 17.847  8.422  1.487  P.aeru P.aeru 
8 1.576  1.120  1.165  CD-3 CD-3 
9 14.836  5.475  1.466  B.mega B.mega 
10 4.605  1.878  1.279  A.azu A.azu 
11 5.406  1.978  1.338  DH5α DH5α 
12 18.279  6.946  1.589  B.liche B.liche 
13 4.381  1.895  1.250  A.azu A.azu 
14 1.880  1.194  1.142  CD-3 CD-3 
15 6.066  2.262  1.324  DH5α DH5α 
16 20.273  7.530  1.568  B.liche B.liche 
17 19.794  9.111  1.370  P.aeru P.aeru 
18 16.566  6.466  1.465  B.liche B.mega 
19 7.353  2.720  1.431  DH5α DH5α 
20 17.404  7.041  1.663  B.liche B.liche 
21 14.372  5.405  1.422  B.mega B.mega 
22 4.690  1.699  1.187  A.azu A.azu 
23 2.055  1.129  1.171  CD-3 CD-3 
24 25.131  11.287  1.560  P.aeru P.aeru 
 
Identifying bacterial biofilms on surfaces such as indwelling devices and implants is a 
critical capability. Determination of pathogens in biofilms occurring on human tissues and organs 
provides an equally important and even more challenging goal. In most cases, the bacterial 
pathogens of interest will be embedded in human tissues within biofilms comprised of, EPS, 
mammalian cells and an extracellular matrix. To test the diagnostic capability of our multi-
channel sensor for wound biofilms, we employed a biofilm-fibroblast cell co-culture
39,40
 as a 
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model. Two bacteria, B. licheniformis and E. coli DH5α were chosen as representative Gram-
positive and Gram-negative species. The bacteria were seeded with a confluent NIH 3T3 (mouse 
fibroblast) cell monolayer
41
 overnight for biofilm formation. The co-cultures were washed before 
sensing to remove planktonic bacteria and non-adherent 3T3 cells. The sensor response patterns 
for B. licheniformis biofilm-3T3 cell, E. coli DH5α-biofilm-3T3 cell, and non-infected 3T3 cell 
were different (Figure 4.6 a), with LDA demonstrating 100% discrimination of the two co-
cultures and 3T3 cells (Figure 4.6 b).  
 
Figure 4.6. Detection and identification of biofilms grown on 3T3 fibroblast cells. a. Triple-
channel fluorescence response patterns in the presence of biofilms grown on fibroblast cells and 
3T3 fibroblast cells alone. I0 is the fluorescence intensity in the absence of biofilms or 3T3 cells. 
Each value is an average of six replicates and the error bars are standard deviations. b. LDA 
canonical score plot of the fluorescence response patterns. 
In the two bacteria/biofilm infected co-cultures, cells were observed to detach and float, 
which were washed away before sensing. Therefore the non-infected 3T3 cells had the highest 
number of mammalian cells. This could be the reason why 3T3 cell culture displayed the highest 
sensor response. As in Figure 4.2, B. licheniformis maintained the higher response than E. coli. 
Besides, the E. coli biofilm co-culture had a greater impact on mammalian cell viability than the 
B. licheniformis biofilm, resulting a lower background response from mammalian cells. As above, 
we tested the ability of this training set to diagnose unknown samples, recognizing 10 out of 12 
samples correctly (Table 4.4). These studies indicate the potential of our system for detection and 
identification of biofilms in infected wounds. 
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Table 4.4. Identification of 12 unknown co-culture samples. 
# I/I0 Identification Verification 
Blue Green Red 
1 1.77 3.54 1.74 Cell B.liche 
2 1.47 1.47 1.51 E.coli E.coli 
3 1.69 3.63 1.71 Cell Cell 
4 1.68 3.72 1.72 Cell Cell 
5 1.53 1.44 1.51 E.coli E.coli 
6 1.63 2.99 1.62 B.liche B.liche 
7 1.75 3.74 1.76 Cell Cell 
8 1.45 1.20 1.47 E.coli E.coli 
9 1.74 3.20 1.69 B.liche B.liche 
10 1.72 3.35 1.70 B.liche B.liche 
11 1.75 3.92 1.69 Cell Cell 
12 1.62 1.87 1.57 B.liche E.coli 
 
4.3 Conclusions 
In conclusion, I have developed a rapid (minutes) and effective multi-channel sensor for 
identifying bacterial species, and even strains, in biofilms. Using this AuNP multi-channel sensor, 
we successfully detected and differentiated biofilms formed by pathogenic and non-pathogenic 
bacteria. These determinations were effective with biofilms on surfaces and in a bacteria-
mammalian cell co-culture wound model. The employed sensing principle demonstrated that 
overall biofilm physiology could be used as an alternative signature for biofilm identification, 
providing a brand new aspect to biofilm research. The selective instead of specific sensor 
construction averts the necessity of pre-knowledge of analyte biofilms, of which very little has 
been known. Beyond this, the described approach allows direct detection and analysis on samples, 
potentially eliminating the need of culturing and therefore false negative diagnosis resulted from 
the non-culturable cells inside biofilms. 
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The optical basis of this system is an added benefit, facilitating translation to both visual
42
 
and camera-based diagnostics.
 43
 Taken together, these capabilities demonstrate the diagnostic 
potential of our sensor system, providing a tool that could enable targeted treatment of biofilm 
infections in lieu of broad-spectrum antibiotics.
 44
 
4.4 Experimental methods 
Fluorescent proteins EBFP2,
 
Error! Bookmark not defined. EGFP,
 45
 and 
tdTomatoError! Bookmark not defined. were expressed in E. coli BL21 (DE3) and purified by 
means of Co2+-affinity chromatography. Cationic NP1 and NP2 were synthesized as previously 
reported.
 46,47
 
Nanoparticle synthesis 2nm diameter gold nanoparticles were synthetized by the Brust-
Schiffrin two-phase methodology using pentanethiol as the stabilizer; these clusters were purified 
with successive extractions with ethanol and acetone. A Murray place exchange reaction was 
carried out in dry DCM to functionalize the nanoparticles with each ligand.
48,49
 The monolayer-
protected nanoparticles were redispersed in water and the excesses of ligand/pentanethiol were 
removed by dialysis using a 10,000 MWCO snake-skin membrane. The final concentration was 
measured by UV spectroscopy on a Molecular Devices SpectraMax M2 at 506nm according to 
the reported methodology.
50
 NPs were characterized on a Malvern Nano Zetasizer to obtain 
hydrodynamic diameter (Figure 4.7) and zeta potential for surface charge (Figure 4.8). 
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Figure 4.7. DLS size distribution of NP1 and NP2. 
 
Figure 4.8. Zeta potential distribution of NP1 and NP2. 
Fluorescence titration 200 nM EBFP2, 200 nM EGFP, and 200 nM tdTomato were 
mixed to make an equimolar solution in 5 mM phosphate buffer (PB, pH=7.4). The solution with 
fixed fluorescent protein concentration was then titrated with NPs at various concentrations from 
0 to 150 nM. For the combination of NP1 and NP2, NPs were first mixed to make an equimolar 
solution, and the NP concentration was defined as the total NP concentration. After 15 minutes 
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incubation at room temperature, the change of fluorescence intensity from three channels was 
measured using a Molecular Devices SpectraMax M2 plate reader. The excitation and emission 
wavelengths are: 380 nm (ex) and 450 nm (em) for EBFP2; 475 nm (ex) and 510 nm (em) for 
EGFP; 550 nm (ex) and 585 nm (em) for tdTomato. Nonlinear least-squares curve-fitting analysis 
by Origin (version 8.0) was employed to estimate the binding constant (Ks) and association 
stoichiometry (n), using a model in which the NP is assumed to possess the n equivalent of 
independent binding sites.
 51
 
Biofilm formation in 96-well microplate Bacteria were inoculated in LB broth at 37 °C 
until stationary phase. The cultures were then harvested by centrifugation and washed with 0.85% 
sodium chloride solution for three times. Concentrations of re-suspended bacterial solution were 
determined by optical density measured at 600 nm. LB was supplemented with 0.1% glucose, 1 
mM MgSO4, 0.15 M ammonium sulphate, and 34 mM citrate and buffered to pH 7 to ensure 
bacterial adherence to the microplate. Seeding solutions were then made in this modified LB to 
reach OD600 of 0.1. 195 μL of the seeding solutions were added to each well of the microplate. 
Modified LB medium without bacteria was used as negative control. The plates were covered and 
incubated at room temperature under static conditions for three days. Fresh media was added on 
Day 2. Planktonic bacteria were removed before sensing by washing with PB saline three times.  
Sensing of biofilms in microplate The sensor was composed of 200 nM EBFP2, 200 nM 
EGFP, 200 nM tdTomato, 80 nM NP1, and 80 nm NP2 in 5 mM PB. The sensor was made fresh 
and incubated in the dark for 15 minutes before use. It was then added (200 μL) into each well 
containing a biofilm and incubated for 45 minutes. The fluorescence recovery was monitored 
using an Optima BMG Labtech plate reader.  
Biofilm-3T3 fibroblast cell co-culture 20,000 NIH 3T3 (ATCC CRL-1658) cells were 
cultured in Dulbecco's modified Eagle medium (DMEM; ATCC 30-2002) with 10% bovine calf 
serum and 1% antibiotics at 37 °C in a humidified atmosphere of 5% CO2. Cells were kept for 48 
hours to reach a confluent monolayer. Bacteria were inoculated and harvested as described above 
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and seeding solutions were made in DMEM to reach OD600 of 0.1. Old medium was removed 
from 3T3 cells followed by addition of 100 μL seeding solution. The co-cultures were then stored 
in a box with damp paper towels at 37 °C overnight. The co-cultures were washed with PB saline 
three times before sensing to remove planktonic bacteria and non-adherent 3T3 cells. 
Sensing of biofilm-fibroblast cell co-cultures The sensor was composed as described 
earlier and was made fresh and incubated in the dark for 15 minutes before sensing. 150 μL of the 
sensing solution was added into each well containing a biofilm and then incubated for 5 minutes. 
The fluorescence recovery was monitored using a Molecular Devices Spectramax M2 plate reader. 
LDA performance Discrimination analysis was performed using SYSTAT (version 
12.0). For biofilm sensing in the microplate, the raw data contained a matrix of 6 (replicates) × 6 
(biofilms) × 3 (channels). The co-culture studies generated a matrix of 6 (replicates) × 3 (biofilms 
plus 3T3 cells alone) × 3 (channels). All raw data were subjected to LDA to differentiate the 
fluorescence response of the multi-channel system against different biofilm targets. The analysis 
maximized the ratio of between-class variance to within-class variance in both data sets, thereby 
enabling maximal separation. The matrixes were transformed to canonical factors that were linear 
combinations of the response patterns. The canonical factors contain different percentage of the 
variation and the first two were plotted.  
The blind test For identification of the unknown samples, we chose seeding solutions of 
interest and assigned them a random number. These seeding solutions were used to form biofilms 
and tested with the multi-channel sensor. The average response of three data points was used to 
represent a single unknown sample. During LDA, the Mahalanobis distance of the unknown case, 
which is the distance of the new case to the centroid of respective groups generated through the 
training set, were calculated. Then the unknown case was classified to the group with the shortest 
Mahalanobis distance.  
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CHAPTER 5 
FUNCTIONAL GOLD NANOPARTICLES AS POTENT ANTIMICROBIAL 
AGENTS AGAINST MULTI-DRUG-RESISTANT BACTERIA 
5.1 Introduction 
The emergence of resistance to antibiotics in bacteria, especially to multiple antimicrobial 
agents, has become a great threat to public health.
1
 According to a report published by the U.S. 
Centers for Disease Control and Prevention, antibiotic resistant bacteria cause millions of 
infections and deaths every year in U.S.
2
 Additionally, the significant and continuous decrease in 
the number of approved antibiotics in the last decade has attributed to the alarming situation.
3
 
Without any alternative novel antibiotics, we may soon encounter the post-antibiotic era.
4
  
Nanotechnology has introduced nanoparticles (NPs) as a new paradigm in therapeutic 
applications with their unique properties.
 5,6,7
 For example, NP size range is commensurate with 
biomolecular and bacterial cellular systems, providing additional interactions to small molecule 
antibiotics.
8,9
  The high surface to volume ratio allows incorporation of abundant functional 
ligands, enabling multivalency on NP surface to enhance interactions to target bacteria. Utilizing 
these characteristic features, NPs have been conjugated with known antibiotics to combat multi-
drug-resistant (MDR) bacteria. The antibiotic molecules can be infused with NPs via non-
covalent interactions
10,11
 or be incorporated on NPs via covalent bonds.
12,13
 Both methods have 
been reported for enhanced activity against bacteria, showing decreased minimum inhibitory 
concentration (MIC) in comparison with use of free antibiotics.
14,15,16
 The improved performance 
is proposed to result from polyvalent effect of concentrated antibiotics on the NP surface as well 
as enhanced internalization of antibiotics by NPs.
17
 Yet the dependence on existing antibiotics in 
these approaches may not be able to delay the onset of acquired resistance. 
The functional ligands on NP surface can provide direct multivalent interactions to 
biological molecules, allowing NPs to be exploited as a self-therapeutic agent.
18,19,20
 This strategy 
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can circumvent the employment and the potential limitation of existing antibiotics in the 
nanocarrier systems. For assembly of such self-therapeutic NPs, the essentially inert and non-
toxic nature of gold makes it an attractive core material.
21
 To this end, we synthesized a series of 
self-therapeutic gold nanoparticles (AuNPs) as an antimicrobial agent. The structure-activity 
relationship of the functional ligands on 2 nm core AuNP revealed that AuNP antimicrobial 
properties can be tailored through surface hydrophobicity, providing a new aspect to design and 
construct antimicrobial AuNPs. According to this relationship, we further focused on the most 
potent AuNP candidate, C10-AuNP, and tested with clinically isolated uropathogens. The result 
showed inhibited growth of various strains of uropathgens, including many MDR strains and 
methicillin-resistant Staphylococcus aureus (MRSA). This AuNP did not induce bacterial 
resistance even after 20 passages. At the MIC against MRSA, the C10-AuNP demonstrated low 
hemolytic activity and cytotoxicity. These results have been written in a manuscript that is ready 
for submission. 
5.2 Results and discussion 
 
Figure 5.1. Molecular structures of functional ligands on AuNPs. 
We recently reported that 2 nm core cationic monolayer-protected AuNPs can interact 
with cell membrane of Gram-positive and Gram-negative bacteria, resulting in formation of 
distinct aggregation patterns and lysis of bacterial cell.
22
  Similarly, Jiang and coworkers also 
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demonstrated that blebbing caused by cationic AuNPs induced bacterial membrane damage.
19
 
Therefore we explored the antimicrobial potential of our 2 nm core functional cationic AuNPs. 
These AuNPs were synthesized with different cationic functionalities to systematically 
investigate the role of surface chemistry in NP antimicrobial property. The thiol ligands bearing 
ammonium end group differed in the functional R group, featuring different chain length, non-
aromatic, and aromatic characteristics (Figure 5.1). 
 
Figure 5.2. MIC values of AuNPs bearing different hydrophobic surface ligands against 
laboratory E. coli. Log P represents the calculated hydrophobic values of the end groups. 
We first evaluated the functional AuNP antimicrobial activities on a laboratory E. coli 
strain, using the broth dilution methods to determine the minimal inhibitory concentrations 
(MICs).
23
 AuNPs were incubated with 5 × 10
5
 cfu/mL of E. coli overnight. All AuNPs were able 
to completely inhibit the proliferation of E. coli at nanomolar concentrations, the MICs of 
different AuNPs, however, varied by the R group. To correlate the antimicrobial activity with 
AuNP surface functionality, we plotted the MICs against the calculated AuNP end group log P 
values that quantitatively represent the relative NP surface hydrophobicity.
24
 Figure 1 uncovered 
the activity-structure relationship, indicating more hydrophobic NPs were more effective against 
E. coli growth. This relationship revealed that the hydrophobic interaction played an important 
role in disruption of bacterial cell wall. Interestingly, NP4 and NP5, which differed with one 
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carbon in structure, exhibited great difference in antimicrobial effectiveness. This could be 
because that NP5 possess more flexibility with the extra space than NP4, leading to more 
effective interaction with bacterial cell wall and therefore stronger damaging to bacterial cell. The 
most hydrophobic AuNP tested, NP3 (C10-AuNP) which carried an n-decane end group, was 
capable of inhibiting E. coli proliferation at only 32 nM. 
We next tested the antimicrobial activities of the most potent antimicrobial NP, NP3, 
C10-AuNP, on uropathogenic E. coli clinical isolates. Five isolates with different resistant levels 
to clinically used antibiotics (number of tested resistant drugs from 1 to 17) were used for this 
study. Remarkably, at a concentration of 16 nM, C10-AuNP suppressed the growth of all five 
uropathogenic strains of E. coli, including three MDR strains (Table 5.1). The comparable MIC 
values of MDR and laboratory strains implicated that C10-AuNP could potentially address the 
common mechanisms of bacterial resistance. 
Table 5.1. MIC values of C10-AuNP against uropathogens. 
Strain Species MIC (nM) # of resistant drugs MDR 
CD-2 E. coli 16 1 No 
CD-496 E. coli 16 2 Yes 
CD-3 E. coli 16 3 Yes 
CD-19 E. coli 16 4 Yes 
CD-549 E. coli 16 17 Yes 
CD-866 E. cloacae complex 16 2 Yes 
CD-1412 E. cloacae complex 8 4 Yes 
CD-1545 E. cloacae complex 16 7 Yes 
CD-1006 P. aeruginosa 16 1 No 
CD-23 P. aeruginosa 32 13 Yes 
CD-1578 S. aureus 64 4 Yes 
CD-489 S. aureus - MRSA 32 10 Yes 
 
C10-AuNP was further tested with more species/strains of uropathogenic clinical isolates, 
including Gram-negative Enterobacter cloacae complex and Pseudomonas aeruginosa and 
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Gram-positive Staphylococcus aureus and methicillin-resistant S. aureus (MRSA) (Table 5.1). 
Among these isolates, P. aeruginosa has intrinsic resistance to a variety of antibiotics due to their 
exceptionally low outer-membrane permeability and multidrug efflux pumps.
25
 MICs of C10-
AuNP for the one non-MDR P. aeruginosa CD-1006 and MDR P. aeruginosa CD-23 were 16 
nM and 32 nM respectively. S. aureus has always been a stumbling block for antimicrobial 
treatment, overcoming most of the therapeutic chemo-agents developed in the past five decades.
26
 
Particularly, MRSA has emerged as “superbug”, resistant to most antibiotics commonly used for 
the staph infections.
27
   C10-AuNP was capable of effectively inhibiting the proliferation of MDR 
S. aureus isolates, and MIC for the MRSA strain was as low as 32 nM. 
In the beginning of our studies, we hypothesized that the cationic functional AuNPs could 
compromise the integrity of bacterial membrane, causing toxicity to bacterial cells.
22
 To support 
this hypothesis and explore C10-AuNP mode of action, we employed the propidium iodide (PI) 
staining assay. PI can only penetrate bacterial cells with compromised membrane and binds with 
nucleic acid with enhanced red fluorescence.
28,29
 E. coli CD-2 and S. aureus CD-489 were chosen 
as representative Gram-negative and Gram-positive strain. Bacteria (1 × 10
8
 cfu/mL) were 
incubated with C10-AuNP at a final concentration of 500 nM for three hours at 37 °C and then 
stained with PI before imaging. Confocal laser scanning microscopy (CLSM) images in Figure 
5.3 showed NP-induced membrane damage in both bacteria. These results indicated that the 
cationic gold nanoparticles use the same mode of action on both Gram-negative and Gram-
positive bacteria. 
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Figure 5.3. CLSM images of PI staining showing NP-induced bacterial cell membrane damage. 
Scale bar is 5 µm. 
To study the development of bacterial resistance to C10-AuNPs, E. coli CD-2 was 
exposed to sub-MIC for sustained passages and the MIC of each passage was tested. Bacteria 
incubated at the sub-MIC concentrations of antibacterial agents were known to develop resistance 
rapidly, especially to conventional antibiotics. After 20 passages in the presence of two thirds of 
C10-AuNP MIC, E. coli remained susceptible to original MIC of 16 nM, indicating that C10-
AuNP did not induce bacterial resistance as quickly as conventional antibiotics. This feature is 
highly valuable in design of novel antimicrobial agents, as it exhibit potential to slow the pace of 
bacterial resistance evolution, providing a way to control and prevent the MDR issue from the 
beginning.
30,31 
 
Figure 5.4. Hemolytic activity of C10-AuNPs at different concentrations. The red cross is an 
estimate of HC 50, the concentration to lyse 50% of human red blood cells, which turns out to be 
around 402 nM. 
To assess the biocompatibility of our antimicrobial C10-AuNP, we performed hemolysis 
assay on human red blood cells as well as viability assay on mammalian cells. At all the MIC 
concentrations tested (in the range of 4 nM to 128 nM), C10-AuNP showed low hemolytic 
activity as shown in Figure 5.4. HC50, which is the concentration to lyse 50% of human red 
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blood cells,
32
 was around 400 nM for C10-AuNP. Therefore the maximum therapeutic index of 
C10-AuNP, which is defined as HC50/MIC, was greater than 50 (402 nM/8 nM). Similarly, after 
treatment with C10-AuNP at all the MIC concentrations tested, NIH-3T3 mammalian cells 
maintained viability was moderately affected (Figure 5.5). At the MIC against the MRSA strain, 
this is 32 nM, the 3T3 fibroblast cell viability maintained around 80%. These studies indicated 
that during the time course tested, C10-NP appeared low hemolytic activity and low cytotoxicity.  
 
Figure 5.5. 3T3 fibroblast cell percent viability when incubated with different concentrations of 
C10-AuNP. 
5.3 Conclusions 
In this chapter, I investigate an antimicrobial strategy using self-therapeutic AuNPs to 
combat MDR bacteria. The cationic functionalized AuNPs effectively suppressed growth of 11 
MDR clinical isolates, including both Gram-negative and Gram-positive bacteria. The NP ligand 
structure-activity relationship revealed that surface chemistry played an important role in AuNP 
antimicrobial property. Such systematic studies are promising in prediction and rational design of 
new antibiotic NPs. Considering the efficient antimicrobial effect on MDR bacteria, the high 
biocompatibility, the slow resistance developing rate, and the ease of surface modification, 
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functionalizing AuNPs can offer a promising alternative defense pathway to (i) combat multi-
drug resistant (MDR) bacteria and (ii) lower the pace of resistance evolution by bacteria. 
5.4 Experimental methods 
Materials All the reagents/materials required for nanoparticle synthesis were purchased 
from Fisher Scientific, except for gold salt, which was obtained from Strem Chemicals Inc. The 
organic solvents were from Pharmco-Aaper or Fisher Scientific and used as received except for 
dichloromethane that was distilled in the presence of calcium hydride. NIH-3T3 cells (ATCC 
CRL-1658) were purchased from ATCC. Dulbecco’s Modified Eagle’s Medium (DMEM) 
(DMEM; ATCC 30-2002) and fetal bovine serum (Fisher Scientific, SH3007103) were used in 
cell culture. 
NP synthesis 2nm diameter gold nanoparticles were synthetized by the Brust-Schiffrin 
two-phase methodology using pentanethiol as the stabilizer; these clusters were purified with 
successive extractions with ethanol and acetone. A Murray place exchange reaction was carried 
out in dry DCM to functionalize the nanoparticles with each ligand.
33,34
 The monolayer-protected 
nanoparticles were redispersed in water and the excesses of ligand/pentanethiol were removed by 
dialysis using a 10,000 MWCO snake-skin membrane. The final concentration was measured by 
UV spectroscopy on a Molecular Devices SpectraMax M2 at 506nm according to the reported 
methodology.
35
 
Determination of antimicrobial activities of cationic gold nanoparticles Bacteria were 
cultured in LB medium at 37 °C and 275 rpm till stationary phase. The cultures were then 
harvested by centrifugation and washed with 0.85% sodium chloride solution for three times. 
Concentrations of re-suspended bacterial solution were determined by optical density measured at 
600 nm. M9 medium was used to make dilutions of bacterial solution to a concentration of 1 × 
10
6
 cfu/mL. 50 µL of these solutions were added into a 96-well plate and mixed with 50 µL of 
NP solutions in M9, giving a final bacterial concentration of 5 × 10
5
 cfu/mL. NPs concentration 
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varied in half fold according to a standard protocol, ranging from 125 nM to 3.9 nM. A growth 
control group without NPs and a sterile control group with only growth medium were carried out 
at the same time. Cultures were performed in triplicates, and at least two independent experiments 
were repeated on different days. The MIC is defined as the lowest concentration of AuNP that 
inhibits visible growth as observed with the unaided eye.
23
 
Propidium iodide staining assay E. coli CD-2 and MRSA CD-489 (1 × 10
8
 cfu/mL) 
were incubated with 500 nM C10-AuNP in M9 at 37 37 °C and 275 rpm for three hours. The 
bacteria solutions were then mixed with PI (2 µM) and incubated for 30 minutes in dark. 5 µL of 
the samples was placed on a glass slide with a glass coverslip and observed with a confocal laser 
scanning microscopy, Zeiss 510 (Carl Zeiss, Jena, Germany) using a 543 nm excitation 
wavelength. 
Resistance development E. coli CD-2 was inoculated in M9 medium with 10.4 nM (2/3 
of 15.6 nM, MIC) at at 37 °C and 275 rpm for 16 hours. The culture was then harvested and 
tested for MIC as describe above. E. coli CD-2 was cultured without NP as well every time as a 
control for comparison of MICs. 
Hemolysis assay Hemolysis assay was performed on human red blood cells as we 
described in previous study.
36
 Briefly, citrate-stabilized human whole blood (pooled, mixed 
gender) was purchased from Bioreclamation LLC, NY. The red blood cells were purified and re-
suspended in 10 mL phosphate buffered saline as soon as received. 0.1 mL of RBC solution was 
added to 0.4 mL of NP solution in PBS in 1.5 mL centrifuge tube.  
The mixture was incubated at 37 ˚C, 150 rpm for 30 minutes followed by centrifugation 
at 4000 rpm for 5 minutes. The absorbance value of the supernatant was measured at 570 nm with 
absorbance at 655 nm as a reference. RBCs incubated with PBS as well as water were used as 
negative and positive control, respectively. All samples were prepared in triplicate. The percent 
hemolysis was calculated using the following formula:  
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% Hemolysis = ((sample absorbance-negative control absorbance)) / ((positive control 
absorbance-negative control absorbance)) × 100. 
Mammalian cell viability assay 20,000 NIH 3T3 (ATCC CRL-1658) cells were cultured 
in Dulbecco's modified Eagle medium (DMEM; ATCC 30-2002) with 10% bovine calf serum 
and 1% antibiotics at 37 °C in a humidified atmosphere of 5% CO2 for 48 hours. Old media was 
removed and cells were washed one time with phosphate-buffered saline (PBS) buffer before 
addition of NPs in the pre-warmed 10% serum containing media. Cells were incubated for 24 h at 
37 °C under a humidified atmosphere of 5% CO2. Cell viability was determined using Alamar 
blue assay according to the manufacturer’s protocol (Invitrogen Biosource, USA). After washing 
with PBS for three times, cells were treated with 220 µL of 10% alamar blue in serum containing 
media abd incubated at 37 °C under a humidified atmosphere of 5% CO2 for three hours. After 
incubation, 200 µL of solution from each wells was transferred in a 96-well black microplate. 
Red fluorescence, resulting from the reduction of Alamar blue solution, was quantified 
(excitation/emission: 560 nm/590 nm) on a SpectroMax M5 microplate reader (Molecular Device) 
to determine the cellular viability. Cells without any NPs were considered as 100% viable. Each 
experiment was performed in triplicates. 
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CHAPTER 6 
SURFACE FUNCTIONALITY CONTROLLED NP PENETRATION INTO 
BACTERIAL BIOFILMS 
6.1 Introduction 
Bacterial biofilm formation plays an important role in many persistent diseases
1
 and 
medical device-associated infections.
2
 These infections are particular challenging, as biofilm 
bacteria are mostly embedded in and protected by the sticky and strong framework fabricated by 
extracellular polymeric substances (EPS).
3
 The EPS matrix possesses complex composition, 
architecture, and dynamic function, which is believed to result in high resistance to antibiotics.
 4
 
For efficient treatment of biofilm-associated infections, it is crucial to understand how the 
complex biofilms and biofilm EPS interact with therapeutic agents, especially with novel 
candidate materials for alternative treatment approach. 
One of the protective properties of EPS comes from its barrier characteristics, which can 
profoundly impede the penetration of antibiotics.
 5
 Moreover, EPS is capable of deactivating 
antibiotics in the surface layers more rapidly than they diffuse, causing limited penetration.
6
 The 
failure of antibiotics to penetrate the full depth of biofilms is one mechanism behind the biofilm 
resistance.
7
 Novel materials such as engineered nanoparticles (NPs) possess strong permeating 
ability into cells,
 8
 tumors,
 9
 and even blood-brain barrier,
10
 presenting a potentially powerful 
vehicle to infiltrate the biofilm EPS barrier.
11
 In addition, the surface functionality of NPs has 
been demonstrated to determine their interactions with biomolecules and cells.
12  
Therefore, 
tailoring the surface chemistry makes NP a controllable probe for study on biofilm EPS 
interaction with engineered materials. 
In this chapter, I report here a study of quantum dots (QDs) as a model fluorescent NP to 
explore the possibility of penetration into biofilms. QDs functionalized with different charges and 
head functional groups were used to systematically investigate the role of surface chemistry in 
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QD penetration and distribution inside biofilms. The results show that cationic QDs can penetrate 
fully into biofilms but neutral and anionic QDs cannot. In addition to the charge effect, NP 
surface hydrophobicity regulates the homogeneity of NP distribution within boifilms. Our studies 
demonstrate that control of surface functionality on NP surface provides an effective approach to 
predict the NP behavior in biofilms (Figure 6.1). These results have been written in a manuscript 
ready for submission. 
 
Figure 6.1. Schematic illustration of surface functionality controlled QD penetration into 
biofilms. Neutral and anionic QDs cannot penetrate into E. coli biofilms, but cationic QDs can. 
6.2 Results and discussion 
Green fluorescent CdSe/ZnS core-shell QDs (emission at 535 nm) were used to prepare 
water soluble QDs through a ligand exchange proces.
13
 Dithiolate ligands
14
 presenting different 
functional head groups were synthesized for QD surface functionalization. The design of ligands 
features a dihydrolipoic acid (DHLA) bidentate anchor, an oligo(ethylene glycol) (OEG) spacer 
and a tunable functional head group.
15
 The terminal functionalities of the ligands were designed 
with different surface charges (i.e., neutral, anionic, and cationic). Additionally, two types of 
cationic ligands were synthesized to incorporate different hydrophobicity on the cationic head 
groups. As shown in Figure 6.2 a, the neutral QDs (PEG-QDs) were prepared by using the 
poly(ethelene glycol)-appended DHLA ligands, and the charged QDs were synthesized with 
different functionalities including carboxyl terminus (COOH-QD), trimethyl ammonium terminus 
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(TTMA-QD), and dimethylhexyl ammonium terminus (Hexyl-QD). The absorption peak 
positions of these QDs were very similar while the emission peaks showed modest differences, as 
is commonly observed after surface modification.
16,17
 Dynamic light scattering data indicated that 
PEG-QD had slightly larger hydrodynamic size of 24 nm, while the other three QDs had 
comparable sizes, ranging from 7.5 to 11.7 nm(Figure 6.2 b). 
 
Figure 6.2. a. Molecular structure of functionalized QD surface ligands. PEG-QD is neutral, 
COOH-QD is anionic, and TTMA-QD and Hexyl-QD are cationic. b. Physical properties of 
functionalized QDs. 
Biofilms were produced on glass cover slips for microscopic study purpose. E.coli strain 
DH5α that expresses E2-crimson, a bright far-red fluorescent protein (emission peak at 646 nm), 
was chosen as a model strain for our study. The biofilms were cultured in a 1/10 strength LB 
broth supplemented with 100 μM IPTG (isopropyl β-D-1-thiogalactopyranoside) according to a 
reported protocol.
18
The penetration experiments were performed on three-day old biofilms for 
one hour incubation with QDs. The cover slips were mounted on glass slides using 4% anti-fade 
mounting solution and examined by confocal laser scanning microscopy (CLSM). 
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Figure 6.3. Representative 3D projection of image z-stacks showing distribution of bacterial cells 
(red) in E.coli biofilms and QDs (green): a, PEG-QD; b, COOH-QD; c, TTMA-QD; d, Hexyl-
QD. Upper panels are projections at 247° angle turning along Y axis and lower panels are at 270° 
angle turning along Y axis. Scale bar is 20 μm. e and f are plot profiles of the three linear 
selection (yellow lines) in c and d, illustrating horizontal distribution of e TTMA-QD and f 
Hexyl-QD. 
The CLSM images were obtained using two different fluorescent channels to detect 
bacterial cells (red fluorescence) and QDs (green fluorescence) simultaneously. Figure 6.3 shows 
the 3D projection of images from a single z-stack to illustrate the overall contribution of QDs to 
the biofilms. In the case of PEG-QD and COOH-QD, there was no pronounced green 
fluorescence observed either on surface or inside the biofilms (Figure 6.3 a and b), indicating no 
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QD penetration during the one hour incubation. The absence of neutral and negative QDs on the 
surface of biofilms was likely due to loose absorption of QDs that was mostly disrupted during 
the washing step. However, Figure 6.3 c and d both display strong green fluorescence from QDs 
throughout the biofilms, indicating the cationic QDs, i.e., TTMA-QD and Hexyl-QD, associated 
with and penetrated into the biofilms. This finding is surprising, since it is reasonable to expect 
the cationic QDs interact with and stick to the negatively charged biofilm EPS and remain in the 
top layers instead of going deeper, but it is in agreement with previous reports where cationic NPs 
were shown to have a better penetration into negative matrix than anionic NPs.
19,20
 Furthermore, 
the different penetration patterns of these two cationic QDs were demonstrated by the projected 
sample images at 270° angle turning along Y axis (Figure 6.3 c and d lower panel). TTMA-QD 
scattered from top layers to bottom layers and accumulated near the bottom of the biofilms while 
Hexyl-QD was more concentrated at middle layers.  
 
Figure 6.4. Zoomed CLSM images of biofilms after 1hr incubation with QDs, showing 
association sites of a TTMA-QD and b Hexyl-QD. The scale bar is 5 μm. 
In addition to the penetration pattern across the biofilm depth, the localization of the 
TTMA-QD and Hexyl-QD was different as shown in the CLSM images. TTMA-QDs were not 
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colocalized with the red fluorescence from the bacteria in the biofilms (Figure 6.4 a), implying 
QD association with EPS. Hexyl-QDs were mostly colocalized with the red fluorescence and 
closely associated to bacterial cells (Figure 6.4 b). Two possible causes for the different 
association sites of the two QDs can be suggested: first, it could be a result from varying binding 
affinities of the QD head groups to different biofilm components, marking different 
hydrophilic/hydrophobic domains of biofilms; second, the NP surface functionality could lead to 
different extracellular diffusion and uptake rates,
9
 and in this case, TTMA-QDs diffused faster 
than being uptaken by bacterial cells, resulting in heterogeneous distribution in blocks of EPS 
(Figure 6.3 c and e, whereas Hexyl-QDs were uptaken faster than diffusion, giving a 
homogeneous dispersion horizontally (Figure 6.3 d and f and concentrated localization in the 
middle layers of biofilms. This observation suggests that rational design of NP surface can 
facilitate selective targeting of biofilm components, for example, EPS matrix, for delivery of 
enzymes to disassociate EPS and induce dispersion of biofilms; or biofilm bacterial cell for 
delivery of antibiotics to kill biofilm bacteria. 
 
Figure 6.5. Integrated intensity of a TTMA-QD and biofilm and b Hexyl-QD and biofilm after 
1hr incubation. The y-axis, normalized intensity, is the integrated QD intensity normalized by the 
integrated biofilm intensity. The x-axis is the depth of penetration of biofilms, where 0 μm 
represents the top and 10 μm represents the bottom. The data are average of three image stacks. 
Error bars are standard deviation. 
To investigate the penetration profiles of the two cationic QDs, three stacks of CLSM 
images taken at random locations were analyzed using ImageJ. For every slice in one image stack, 
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the green and red channels were separated and then analyzed for integrated intensity within a 
fixed 512×512 frame. The integrated intensity from the green and red channel hence represented 
the intensity of QDs and bacteria in the biofilms, respectively. The integrated intensity from both 
channels was plotted versus the biofilm depth to illustrate the distribution of biofilms and QDs. 
Both TTMA-QD and Hexyl-QD were present at 7.2 μm biofilm depth, which displayed the 
average highest area coverage, representing the very bottom layer of biofilms (Figure 6.5 a and b). 
This result reveals that both QDs penetrated the full biofilm depth.  
 
Figure 6.6. The penetration profile of TTMA-QD 1hr (square, solid), Hexyl-QD 1hr (circle, 
solid), TTMA-QD 3hr (square, empty), and Hexyl-QD 3hr (circle, empty). The y-axis, 
normalized intensity, is the integrated QD intensity normalized by the integrated biofilm intensity. 
The x-axis is the depth of penetration of biofilms, where 0 μm represents the top and 10 μm 
represents the bottom. The data are average of three image stacks. 
The biofilm 3D architecture is inherently heterogeneous, causing the biofilm mass 
distribution vary among the three image stacks. Thus the integrated QD intensity was normalized 
by the biofilm intensity at the same step was plotted versus the biofilm depth. In Figure 6.6, 
TTMA-QD presented a relatively even dispersion along the vertical direction of biofilms and the 
highest density at 7.2 μm.  Hexyl-QD, however, exhibited a different pattern in which the density 
increased till a peak value around 4.4 μm and then decreased. Moreover, Figure 6.6 indicates that 
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Hexyl-QD had an overall higher density than TTMA-QD. The QD penetration profiles were 
further investigated after a longer incubation time. No significant change of distribution was 
observed for both QDs after different incubation periods (Figure 6.6). This result indicates that 
the penetration of these two QDs occurred rapidly and reached a stabilized state within one hour. 
6.3 Conclusions 
In summary, we employed functionalized QDs to demonstrate that by engineering surface 
properties NPs can be tailored to penetrate biofilms. The engineered NPs provide a promising 
scaffold to effectively protect and carry antibiotics through the EPS barrier. Furthermore, NPs 
may be engineered to possess antimicrobial characteristics, attributing as antimicrobial agents 
themselves upon penetration.  
Nanotechnology has attracted much attention and number of studies on how to utilize 
nanomaterials as novel antimicrobial agents has intensively increased. However, the interaction 
between nanomaterials and microorganisms is a fundamental question that is needed to be 
answered for application purpose. As an extension of bacterial life, biofilms have been taken into 
consideration when testing nanoparticle antimicrobial properties. This study not only provides a 
methodology for easy visualization of such material interaction with biofilms, but also reveals the 
important factors in regulation of such interactions.  
Taken together, by accommodating surface functionality to infiltrate biofilms, it provides 
a new exciting strategy for designing NPs to penetrate biofilms and to combat biofilm resistance, 
offering a potential approach for a low-stress, surgery-free, and efficient treatment of biofilm-
associated infections. 
6.4 Experimental methods 
Materials All chemicals were purchased from Sigma-Aldrich unless otherwise stated. 
The organic solvents were bought from Fisher and used as received while dichloromethane 
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(DCM) was distilled in the presence of calcium hydride. Flash column chromatography was 
performed for purification using silica gel (SiO2, particle size 40-63 µm). Milli-Q water from a 
Millipore Simplicity 185 system (Millipore Corp., Billerica, MA) was also used to prepare 
samples.  
Synthesis of water soluble ligands The syntheses of DHLA-PEG-OH
 
and DHLA-
TEG-N(CH3)2-Rn ligands have been reported in the published literature.
21
  DHLA-TEG-COOH 
ligands were synthesized in a stepwise procedure (Figure 6.7 b). Briefly, Compound 1 (2 g, 5.2 
mmol) was dissolved in 30 ml dry THF (30 ml). DMAP (0.64 g, 5.2 mmol) and DIPEA (0.67 g, 
5.2 mmol) were added to the solution and stirred for 5 mins. Succinic anhydride (1.57 g, 15.6 
mmol) was added to the solution and stirred for 24 h at room temperature. The reaction mixture 
was evaporated under reduced pressure to remove the solvent, and further diluted with water and 
extracted with DCM. Compound 2 was obtained by using column chromatography with 100 % 
EtOAc as eluent. NaBH4 was used to reduce the disulfide bond to obtain the final product 
DHLA-TEG-COOH. 
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Figure 6.7. a. Structures of the ligands used in the studies. b. Synthetic route of DHLA-TEG-
COOH ligand. Reagents and conditions: (i) EDC, HOBt, DIPEA, DCM, r.t., 24 h; (ii) DMAP, 
DIPEA, succinic anhydride, THF, r.t., 24 h; (iii) NaBH4, EtOH/ H2O, r.t., 1 h 
1
H NMR (400 MHz, CDCl3) of DHLA-TEG-COOH: δ 4.24 (t, 4H, COO-CH2-CH2 and 
CH2-CH2-OOC-) 3.74-3.62 (m, 12H, -CH2-TEG-), 2.59-2.51 (brm, 2H, COO-CH2-CH2-COOH), 
2.47-2.40 (brm, 2H, COO-CH2-CH2-COOH), 2.36 (t, 2H, CH2-CH2-COO), 1.75-1.62 (m, 4H), 
1.58-1.39 (m, 2H). 
Preparation of water soluble QDs CdSe/ZnS core-shell QDs were synthesized 
according to the reported procedure. The preparations of PEG-QDs and COOH-QDs were 
through a ligand exchange process.
21
 DHLA-PEG-OH or DHLA-TEG-COOH ligands have 
placed in DCM under ligand to hydrophobic trioctylphosphine oxide/trioctylphosphine 
(TOPO/TOP)-capped QDs ratio by weight (3: 1), and the solution was stirred at 35 
o
C for 24 h. 
After 24 h of stirring, DCM was evaporated and the resultant QDs were dispersed in Milli-Q 
water and purified by dialysis.  The preparation of cationic QD (i.e., TTMA-QDs and Hexyl-QDs) 
was through a two-step ligand exchange reaction. Briefly, hydrophobic TOPO/TOP-capped QDs 
were mixed with amphiphilic HS-(CH2)5-TEG-OH ligands in MeOH and the reaction mixture 
was stirred at 35 
o
C for 24 h. Next step involved the purification of amphiphilic QDs with hexane 
and the addition of DHLA-TEG-N(CH3)2-Rn ligands to the amphiphilic QDs in MeOH. After 24 
h of stirring, MeOH was evaporated and the dithiolate cationic QDs were dispersed in Milli-Q 
water and purified by dialysis. 
DLS and zeta potential DLS experiments and zeta potential measurements were 
performed using a Malvern Zetasizer (Nano series, Malvern Instruments Inc, USA). Samples 
were sonicated and filtered with 0.2 µm syringe filter before measurement.    
Biofilm culture Bacteria were inoculated in 3 mL LB broth and grown to stationary 
phase at 37 °C. The cultures were then diluted 1:100 in a 1/10 strength LB broth supplemented 
with 100 μM IPTG (isopropyl β-D-1-thiogalactopyranoside). 25 mL of the dilution was 
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transferred into a petri dish containing six sterile glass cover slips (22 × 22 mm). The petri dish 
was kept at 25 °C and the biofilms were allowed to grow for three days. In general, the cover 
slips with biofilms were rinsed in deionized water for three times before placed in QD solutions. 
The biofilms were incubated in 300 nM QD solutions and free QDs were washed away by rinsing 
in deionized water for three times. 
CLSM image The CLSM images were obtained using Zeiss510 META. The green 
fluorescent channel was collected at 488/505-550 bad pass and the red fluorescent channel was 
collected at 543/560 longpass. 
6.5 Supplementary information 
 
Figure 6.S1. Representative CLSM image slices of z-stack with a 0.4 μm interval showing 
bacterial cells (red) in E.coli biofilms and distribution of PEG-QD. The 3D projection of these 
slices is displayed in Figure 6.3 a. for a clear demonstration. The absence of green fluorescence 
from PEG-QD indicates no neutral QD absorbance or penetration occurred within the one hour 
incubation time. The scale bar is 20 µm. 
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Figure 6.S2. Representative CLSM image slices of z-stack with a 0.4 μm interval showing 
bacterial cells (red) in E.coli biofilms and distribution of COOH-QD. The 3D projection of these 
slices is displayed in Figure 6.3 b. for a clearer demonstration. The absence of green fluorescence 
from COOH-QD indicates no anionic QD absorbance or penetration occurred within the one hour 
incubation time. The scale bar is 20 µm. 
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Figure 6.S3. CLSM image stacks used for analysis of TTMA-QD penetration profile after 1 hr 
incubation. The scale bar in these images is 20 µm. 
In analysis, each image slice is split into green channel and red channel. The green 
channel represents QD distribution, and the integrated intensity is obtained in ImageJ. The red 
channel represents biofilm distribution, and the integrated intensity is also obtained in Image J. At 
each depth, values from these three stacks were averaged. The green channel mean integrated 
intensity values and the red channel mean integrated intensity values were plotted versus the 
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biofilm depth to make Figure 6.5 a. The green channel mean value was normalized by the mean 
value from red channel to make Figure 6.6. 
 
Figure 6.S4. CLSM image stacks used for analysis of Hexyl-QD penetration profile after 1 hr 
incubation. The scale bar in these images is 20 µm. 
In analysis, each image slice is split into green channel and red channel. The green 
channel represents QD distribution, and the integrated intensity is obtained in ImageJ. The red 
channel represents biofilm distribution, and the integrated intensity is also obtained in Image J. At 
each depth, values from these three stacks were averaged and the mean value was plotted versus 
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the biofilm depth. The green channel mean integrated intensity values and the red channel mean 
integrated intensity values were plotted versus the biofilm depth to make Figure 6.5 b. The green 
channel mean value was normalized by the mean value from red channel to make Figure 6.6. 
 
Figure 6.S5. CLSM image stacks used for analysis of TTMA-QD penetration profile after 3 hr 
incubation. The scale bar in these images is 20 µm. 
In analysis, each image slice is split into green channel and red channel. The green 
channel represents QD distribution, and the integrated intensity is obtained in ImageJ. The red 
channel represents biofilm distribution, and the integrated intensity is also obtained in Image J. At 
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each depth, values from these three stacks were averaged and the mean value was plotted versus 
the biofilm depth. The green channel mean value was normalized by the mean value from red 
channel to make Figure 6.6. 
 
 
Figure 6.S6. CLSM image stacks used for analysis of Hexyl-QD penetration profile after 3 hr 
incubation. The scale bar in these images is 20 µm. 
In analysis, each image slice is split into green channel and red channel. The green 
channel represents QD distribution, and the integrated intensity is obtained in ImageJ. The red 
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channel represents biofilm distribution, and the integrated intensity is also obtained in Image J. At 
each depth, values from these three stacks were averaged and the mean value was plotted versus 
the biofilm depth. The green channel mean value was normalized by the mean value from red 
channel to make Figure 6.6. 
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CHAPTER 7 
ANTIMICROBIAL GOLD NANOPARTICLES FOR INHIBITION AND 
REMOVAL OF BACTERIAL BIOFILMS 
7.1 Introduction 
Clinical practice that deals with device-related and other chronic bacterial infection 
increasingly faces a new type of infectious disease, which is quite distinguished from acute 
bacterial infection. Compared to acute infections, these diseases are much less aggressive, and 
they often progress through periods of latency alternating with periods of acute exacerbation, 
persisting for months or years. These chronic infections are found to be associated with bacterial 
biofilm.
 1 , 2
 For example, infectious diseases such as native valve endocarditis, otitis media, 
periodontitis, and chronic wounds appear to be caused by biofilm-associated microorganisms.
3
 
Biofilms are also responsible for infections on implants and indwelling medical devices, 
including replacement joints, prosthetic heart valves, and urinary catheters.
4
 Biofilm infections 
are chronic with a low-grade immune response and thus are rarely resolved by the host defense 
mechanism.
5
 Despite the relief during the exacerbation periods provided by traditional antibiotic 
therapy via killing bacteria released from biofilms, most antibacterials are rarely effective against 
biofilms. 
A bacterial biofilm is a complex community assembled by bacterial cells within an 
extracellular polymeric substance (EPS) matrix. The formation of biofilms is a protecting strategy 
that allows bacteria to survive in hostile environment. Within the three dimensional structures of 
biofilms, there are channels formed for nutrition circulation
6
 and different regions in which 
bacterial cells exhibit various patterns of gene expression.
7
  This structural and metabolic 
complexity of biofilms has lead to the analogy of biofilms to tissues of higher organisms. Non-
sessile individuals, planktonic bacteria that are capable of rapid dispersion and proliferation, can 
be released from these sessile biofilm communities. The release of such planktonic bacteria is for 
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biofilm expansion as well as protection, as these non-sessile bacteria are exposed to deleterious 
agents in their environment, be they phage or amoeba in nature or potent antimicrobial agents in a 
clinical setting. Thus it is only reasonable that a great number of bacterial infections involves with 
biofilms, which are challenging to eradicate with conventional antibiotic treatment. 
 
Figure 7.1. Three hypotheses for mechanisms of antibiotic resistance in biofilms. The attachment 
surface is shown at the bottom and the aqueous phase containing the antibiotic at the top. Adapted 
from reference 10. 
There are three main hypotheses behind the mechanism of reistance to antibiotics in 
bacterial biofilms (Figure 7.1).
8
 One mechanism of biofilm resistance to antibiotics is the failure 
of antibiotics to penetrate the full depth of biofilms. The penetration of antibiotics can be 
profoundly retarded due to the barrier properties of the sticky and strong extracellular polymeric 
substance (EPS).
 9,10
 Moreover, EPS is capable of deactivating antibiotics in the surface layers 
more rapidly than they diffuse, causing limited penetration.
11,12
 For example, ampicillin cannot 
penetrate a biofilm formed by the β-lactamase-positive wild-type strain of K. pneumonia. 13 The 
second hypothesis relies on a chemical microenvironment that is altered inside biofilms. Nutrition 
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and oxygen are likely to be consumed in the surface layers of a biofilm, leading to nutrition 
depletion and anaerobic niches in the deep layers of the biofilms.
14
 These conditions might push 
some bacteria to enter a non-growing state, protecting them from being killed by antibiotics such 
as penicillin antibiotics, which target cell-wall synthesis, kill only growing bacteria.
15
 Besides, 
local accumulation of acidic metabolic waste products can result in pH differences greater than 
between the bulk fluid and the biofilm interior,
16
 which could directly antagonize the action of an 
antibiotic. Additionally, an osmotic stress response might be induced by altered osmotic 
microenvironment within a biofilm, and such a response could change the relative proportions of 
porins to reduce cell envelope permeability to antibiotics, contributing to antibiotic resistance 
within a biofilm.
17
 A third yet still speculative mechanism is a subpopulation of bacteria that is in 
a unique and highly protected phenotypic state.  
 Nanoparticles (NPs) possess strong permeating ability into cells,
 18
 tumors,
 19
 and even 
blood-brain barrier,
20
 presenting a potentially powerful vehicle to infiltrate the biofilm EPS 
barrier. In addition, the surface functionality of NPs has been demonstrated to determine their 
interactions with biomolecules and cells.
21,22 
Therefore, tailoring the surface chemistry makes NP 
a controllable platform for overcoming biofilm EPS barrier. Moreover, we have demonstrated 
that functionalized cationic gold nanoparticles can be used as potent antimicrobials against 
bacteria and even multi-drug-resistant bacteria. 
Since biofilms are extremely difficult to treat once they are formed, a great portion of 
research and clinical efforts is focused on how to prevent formation of biofilms. In this chapter, I 
first examine if functional cationic gold nanoparticles (AuNPs) can be used to inhibit formation 
of biofilms and the relationship of effective AuNP concentrations against biofilms with MIC 
against planktonic bacteria. Next I probe the possibility of treatment of formed biofilms with 
AuNPs and discuss possible future plans based these results. 
 102 
 
7.2 Results and discussion 
I have demonstrated in Chapter 5 that our functionalized cationic C10-AuNP can inhibit 
both gram-positive and gram-negative pathogens, even multi-drug-resistant pathogens. Therefore, 
in this study, we employed C10-AuNP for pioneer studies. As shown in Figure 7.2, C10-AuNP 
features positive charge and a long hydrophobic 10 carbon chain at the head group. The proposed 
mode of action is that C10-AuNP can disrupt bacterial cell membrane and cause bacterial death. 
The long alkyl chain is hydrophobic, which is believed to be additional interaction to cationic 
charge when in contact with bacterial cell surface. 
 
Figure 7.2. Molecular structure of functionalized cationic C10-AuNP. 
C10-AuNP and one antibiotic drug, kanamycin, were tested for their MIC against 
bacteria E. coli and P. aeruginosa respectively. The choice of these two model bacteria is due to 
their relevance to the clinical formed biofilms. The MICs of C10-AuNP against E. coli and P. 
aeruginosa were both 16 nM, and the MICs of kanamycin against E. coli and P. aeruginosa were 
4 µg/mL and 16 µg/mL respectively. AuNPs were mixed in culture medium, M9, at different 
folds of MIC and incubated with both E. coli and P. aeruginosa. Kanamycin was used at the same 
folds of MIC as AuNPs for comparison purpose. Biofilms were cultured for one day to test the 
inhibition effect in a short-time period, and biofilms were also cultured for two days to test AuNP 
and kanamycin’s ability to prevent biofilm formation in a longer time period. Biofilms in medium 
without AuNPs nor kanamycin were used as control and counted as 0% inhibition. 
As shown in Figure 7.3 a, within one-day period, kanamycin failed to inhibit E. coli 
biofilm formation at sub-MIC concentrations, and its inhibitory effect started to show only at 5 
folds of MIC against planktonic E. coli. At lower concentrations, kanamycin even promoted 
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biofilm formation (% inhibition value lower than 0). On contrast, C10-AuNP was able to inhibit 
E. coli biofilm formation up to 75% at 0.75 fold of MIC against planktonic bacteria. And at 5 
folds MIC concentration, there was almost no E. coli biofilm formation. Compared with E. coli, 
kanamycin worked more effectively on P. aeruginosa biofilm (Figure 7.3 b). Both kanamycin 
and AuNP displayed inhibitory effect at sub-MIC concentrations and both were capable of 
preventing P. aeruginosa biofilm formation up to around 75% at only half fold of MIC against 
planktonic bacteria. However, AuNP was able to completely inhibit P. aeruginosa biofilm 
formation at higher concentrations, whereas kanamycin could only maintain around 75% 
inhibitions even at higher concentrations. 
 
Figure 7.3. Inhibition of a. one-day old biofilm and b. two-day old biofilms of E. coli in the 
presence of C10-AuNP (black solid square) and kanamycin (black empty square) and P. 
aeruginosa in the presence of C10-AuNP (red solid triangle) and kanamycin (red empty triangle). 
Data are average of triplicates and error bars are standard deviation. 
For a two-day incubation period (figure 7.3 b), E. coli biofilm formed at lower 
concentrations of kanamycine, and biofilm was only inhibited around 60% at 5 folds of MIC 
against planktonic bacteria. However, C10-AuNP reached similar inhibition effect only at half 
fold of MIC against planktonic E. coli, and the inhibition effect became stronger with the 
increasing AuNP concentrations. And at 5 folds of MIC against planktonic bacteria, E. coli 
biofilm formation was almost completely prevented. P. aeruginosa biofilms, however, were more 
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difficult for kanamycin to inhibit for a two-day incubation time. In fact, kanamycin failed to 
inhibit P. aeruginosa biofilm at all tested concentrations. AuNP, instead, maintained inhibitory 
effect against P. aeruginosa biofilm formation. At lower sub-MIC, AuNP still exhibited 
antibiofilm property and suppressed P. aeruginosa biofim formation to 20% and the suppressing 
effect increased with increasing AuNP concentration. When cultured with 5 folds of AuNP MIC 
against planktonic bacteria, there was almost P. aeruginosa biofilm formed. 
This study supported that biofilm formation became more challenging with longer 
incubation/infection time. Results also revealed that the efficiency of traditional antibiotic therapy 
dropped dramatically with increasing incubation time course. However, the efficiency of AuNPs 
did not drop as much as kanamycin. On the contrary, at 5 folds of MIC against plaktonic bacteria, 
AuNPs were able to completely inhibit both E. coli and P. aeruginosa biofilm formation for up to 
two days. Longer incubation periods will be tested in the future work to explore the lasting 
efficiency of C10-AuNP against E. coli and P. aeruginosa biofilm formation. 
After success in inhibiting biofilm formation, I am interested to probe the possibility of 
eradication of formed biofilms by C10-AuNP. For this purpose, I chose P. aeruginosa biofilm 
which is closely related to clinical chronic infections. Especially, chronic clinical bacterial 
infections with P. aeruginosa have an important role in pulmonary infection in cystic fibrosis 
(CF). The majority of patients with CF acquired P. aeruginosa that grows within microcolonies in 
the airways, causing chronic lung infection and repeated exacerbations and progressive 
deterioration in lung function, which remained major causes of morbidity and mortality.  
P. aeruginosa biofilms were cultured in M9 for one day, and old medium was replaced 
with fresh M9 containing different concentrations of C10-AuNPs. After one day treatment, 
biofilms metabolic activity was examined to measure viability of remaining biofilms. When 
treated with sub-MIC concentrations and concentrations slightly higher than MIC, P. aeruginosa 
biofilms were not effectively eradicated. Higher AuNP concentrations increased the killing 
efficiency and at 50 folds of MIC against planktonic bacteria, the original one day old P. 
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aeruginosa biofilm was killed for around 80%. No higher killing efficacy was obtained at tested 
AuNP concentrations. Noticeably, though P. aeruginosa biofilms were only one-day old before 
treatment, however, when incubated with AuNPs, biofilms were still in medium. Therefore, there 
could be the possibility of re-growth from remaining biofilms after being partially killed by 
AuNPs at lower concentrations. This result again demonstrated the drastically increased 
resistance in biofilms to planktonic bacteria. Results showed promising potential for treatment of 
biofilms using our functionalized cationic AuNPs. 
 
Figure. 7.4. The killing effect of C10-AuNP against one-day old P. aeruginosa biofilm. The 
biofilms were treated with AuNP for one day, and %killing is calculated by 100% minus 
the %viability of remaining biofilms after treatment. Data are average of triplicates and error bars 
are standard deviation.  
7.3. Conclusions 
In this chapter, I demonstrate that functional antibacterial AuNPs possess antibiofilm 
property as well. AuNPs successfully inhibited biofilm formation for up to two days at five folds 
of MIC against planktonic bacteria. Furthermore, this C10-AuNP eradicated 80% of P. 
aeruginosa biofilms. The proposed the working mechanism is the strong penetration ability plus 
the bacterial cell membrane disrupting ability of AuNPs. Though the effective AuNP 
concentrations are not high to inhibit biofilm formation, higher concentrations are required for 
eradication of biofilms. For treatment of more mature biofilms, therefore, one can rationally 
assume that even higher concentrations are necessary. Considering the penetration and membrane 
disrupting ability, AuNPs may be combined with other antimicrobial agents to facility these 
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antimicrobial agents penetration into biofilms as well as entry and uptake into bacterial cells, and 
thus increase antibiofilm efficiency while circumventing potential toxicity of high dosage of 
AuNPs. Following this strategy, research focused on combination therapy of AuNPs and 
conventional antibiotics is currently conducted by my junior research colleague. 
7.4 Experimental methods 
Materials All the reagents/materials required for nanoparticle synthesis were purchased 
from Fisher Scientific, except for gold salt, which was obtained from Strem Chemicals Inc. The 
organic solvents were from Pharmco-Aaper or Fisher Scientific and used as received except for 
dichloromethane that was distilled in the presence of calcium hydride. NIH-3T3 cells (ATCC 
CRL-1658) were purchased from ATCC. Dulbecco’s Modified Eagle’s Medium (DMEM) 
(DMEM; ATCC 30-2002) and fetal bovine serum (Fisher Scientific, SH3007103) were used in 
cell culture. 
NP synthesis 2nm diameter gold nanoparticles were synthetized by the Brust-Schiffrin 
two-phase methodology using pentanethiol as the stabilizer; these clusters were purified with 
successive extractions with ethanol and acetone. A Murray place exchange reaction was carried 
out in dry DCM to functionalize the nanoparticles with each ligand. The monolayer-protected 
nanoparticles were redispersed in water and the excesses of ligand/pentanethiol were removed by 
dialysis using a 10,000 MWCO snake-skin membrane. The final concentration was measured by 
UV spectroscopy on a Molecular Devices SpectraMax M2 at 506nm according to the reported 
methodology. 
Determination of antimicrobial activities of cationic gold nanoparticles Bacteria were 
cultured in LB medium at 37 °C and 275 rpm till stationary phase. The cultures were then 
harvested by centrifugation and washed with 0.85% sodium chloride solution for three times. 
Concentrations of re-suspended bacterial solution were determined by optical density measured at 
600 nm. M9 medium was used to make dilutions of bacterial solution to a concentration of 1 × 
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10
6
 cfu/mL. 50 µL of these solutions were added into a 96-well plate and mixed with 50 µL of 
NP solutions in M9, giving a final bacterial concentration of 5 × 10
5
 cfu/mL. NPs concentration 
varied in half fold according to a standard protocol, ranging from 125 nM to 3.9 nM. A growth 
control group without NPs and a sterile control group with only growth medium were carried out 
at the same time. Cultures were performed in triplicates, and at least two independent experiments 
were repeated on different days. The MIC is defined as the lowest concentration of AuNP that 
inhibits visible growth as observed with the unaided eye.  
Biofilm culture Bacteria were inoculated in LB broth at 37 °C until stationary phase. The 
cultures were then harvested by centrifugation and washed with 0.85% sodium chloride solution 
for three times. Concentrations of re-suspended bacterial solution were determined by optical 
density measured at 600 nm. Seeding solutions were then made in M9 to reach OD600 of 0.1. 100 
μL of the seeding solutions were added to each well of the microplate. M9 medium without 
bacteria was used as negative control. The plates were covered and incubated at room 
temperature under static conditions for desired period. Planktonic bacteria were removed before 
sensing by washing with PB saline three times. 
Determination of biofilm inhibition activities of cationic gold nanoparticles and 
kanamycin Kanamycin and AuNP solutions were prepared at different concentrations in M9 
respectively. These solutions were then seed with bacteria. After incubation, the biofilms were 
washed with PB saline for three times and stained with 0.1 % crystal violet staining solution for 
15 minutes. This was followed by washing with PBS till no purple color observed in washing 
buffer. The plate was then left to dry in air. After drying, the plates were distained with 80% 
ethanol/20% acetone mixture for 15 minutes. The absorbance at 590 nm was measure afterwards. 
The higher absorbance represented more biofilm formation. 
Determination of biofilm killing activities of cationic gold nanoparticles AuNP 
solutions were prepared at different concentrations in M9 and these solutions were then put into 
the one-day old P. aeruginosa biofilm. Biofilms were treated for one day at room temperature 
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and then washed with PBS for three times. After washing, alamar blue solution in PBS was added 
and the plate was incubated at 37 °C for two hours. After incubation the plates were measured in 
a plate reader at 545 nm/590 nm (ex/em). 
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CHAPTER 8 
NANOPARTICLE-BASED CAPSULES FOR TREATMENT OF BIOFILMS 
8.1 Introduction 
Bacterial biofilms are widely associated with persistent infections.
1
  These biofilm 
infections occur frequently on implants and indwelling medical devices, including urinary 
catheters,
2
 arthro-prostheses,
3
 and dental implants.
4
  Biofilms can also form on dead or living 
tissues, leading to endocarditis,
5
 otitis media,
6
 cystic fibrosis,
7
 and chronic wounds.
8
  These 
infections and diseases are notoriously difficult to treat, as biofilms develop high resistance to 
host immune responses as well as conventional antibiotics.
9
  For these reasons biofilm-associated 
infections are commonly treated by excision of the infected parts combined with long-term 
antibiotic therapy, incurring high health care costs and immense patient stress.
10
   
Plant-derived compounds, especially essential oils, have offered an alternative source to 
traditional antimicrobial agents to combat antibiotic resistant bacteria
11 , 12
  The antibacterial 
properties of these essential oils have been demonstrated by their long history of use in medicine 
for prevention and treatment of infections.
13
  Recent studies revealed that these natural 
compounds also possess anti-biofilm characteristics.
14,15
  However, the poor solubility of such oils 
has substantially limited their widespread application.  Previous reports have shown that 
encapsulating essential oils into colloidal delivery vehicles improves their stability and 
activity.
16,17,18
   Pickering emulsions are a particularly attractive alternative to dynamic surfactant 
stabilizers for encapsulation, as the generated droplets possess functionalized particles that remain 
embedded at the interface.
19 , 20 , 21
  Furthermore, nanoparticle stabilized emulsions can create 
dermal delivery vehicles with high payload to carrier ratios.
22
    
Herein we describe the fabrication of an essential oil containing capsule stabilized by 
silica nanoparticles for the treatment of biofilms.  Silica nanoparticles functionalized with surface 
amines stabilize the oil in water emulsions.  The nanoparticles provide a cationic shell around the 
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oil droplets promoting interaction with the anionic biofilm matrix.  Peppermint oil and 
peppermint oil doped with cinnamaldehyde were used as model hydrophobic cores.  The 
cinnamaldehyde reacted with the amines of the nanoparticle to crosslink the nanoparticles at the 
oil/water interface generating a more effective delivery vehicle.  The synergistic delivery of the 
peppermint oil doped with cinnamaldehyde effectively treated biofilm infections in a co-culture 
fibroblast system.  Capsules were able to eradicate the biofilm while preserving the viability of 
the underlying fibroblasts. These results are being prepared in a manuscript for publication.  
 
Figure 8.1. Schematic illustration of SiO2 NP-based essential oil capsules. 
8.2 Results and discussion 
We first fabricated capsules consisted of only peppermint oil core (P-Cap) and capsules 
containing peppermint oil and cinnamaldehyde core (C-Cap). Capsules were freshly made before 
use and a 2% stock solution was made for all experiments. Solutions containing different capsule 
concentrations were made from the 2% stock solution. SiO2 NPs alone and peppermint oil only 
were used as control, and these control solutions were made to contain the same amount of SiO2 
NP or peppermint oil as the capsule solutions at corresponding capsule solutions. 
To test the biofilm killing capability of these capsules in a short time period, we first 
employed one day-old biofilm and treated them for three hours. E. coli and P. aeruginosa 
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biofilms were chosen as model biofilms due to their relevance to clinical biofilm-associated 
infections. After three hour treatment and washing, viability of the remaining biofilms were 
evaluated and normalized by the viability of non-treated biofilms (0%). As shown in Figure 8.2 a, 
the one day-old E. coli biofilms viability did not decease by SiO2 NP, indicating SiO2 NPs alone 
were not harmful for bacterial biofilms. When treated with peppermint oil alone, which acted as 
antimicrobial agent itself, the one day-old E. coli biofilm viability decreased to around 60% at 50% 
concentration and around 10% at 100% concentration. P-Cap containing the same amount of 
peppermint oil, however, did not show as high anti-biofilm effect as peppermint oil, and the one 
day-old E. coli biofilm viability only dropped to around 75% at the highest concentration tested. 
C-Cap possessed the highest biofilm killing capability and eradicated almost 100% one day-old E. 
coli biofilms at 50% concentration.  
 
Figure 8.2. Viability of a. one day-old E. coli biofilms and b. one day-old P. aeruginosa biofilms 
after three hour treatment with different concentrations of capsules containing peppermint oil and 
cinnamaldehyde (C-Cap, black), capsules containing only peppermint oil (P-Cap, red), SiO2 NP 
(green), and peppermint oil (Ppmt Oil, blue). Data are average of triplicates and error bars are 
standard deviation. 
Similarly for one day-old P. aeruginosa biofilms, SiO2 NP did not significantly affect 
their viability except at the highest concentration; peppermint oil reduced biofilm viability; P-Cap 
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reduce biofilm viability as well but as much as peppermint oil alone; C-Cap showed the highest 
biofilm killing property and reduced biofilm viability to around 40% at 20% concentration. 
 
Figure 8.3. Viability of a. one day-old E. coli biofilms and b. one day-old P. aeruginosa biofilms 
after one day treatment with different concentrations of capsules containing peppermint oil and 
cinnamaldehyde (C-Cap, black), capsules containing only peppermint oil (P-Cap, red), SiO2 NP 
(green), and peppermint oil (Ppmt Oil, blue). Data are average of triplicates and error bars are 
standard deviation. 
As proposed earlier in Chapter 7, when treated with antibiotilm agents for a longer time, 
biofilms could recover from initial shocking stage. Therefore, in next step we tested both capsules 
and control groups on the one day-old biofilms for longer treatment time, one day period. As 
displayed in Figure 8.3, SiO2 NP was still not harmful for one day-old E. coli biofilm after one 
day treatment. The killing effect of peppermint oil was not as effective as three hour treatment, 
and in fact at 100% concentration, peppermint oil treated one day-old E. coli biofilm viability was 
only reduce to around 75% after one day treatment, which was 60% higher than that after three 
hour treatment. This result indicated that though peppermint oil could suppress biofilm viability 
in a short time course, it could not consistently control or kill biofilms after the initial shocking 
stage. To the opposite, P-Cap containing the same amount of peppermint oil showed better killing 
and controlling property in the longer treatment period. And C-Cap remained effective on one 
day-old E. coli biofilm in the one day treatment period. Similar trends were observed in one day-
old P. aeruginosa biofilms after one day treatment. 
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These initial results demonstrated the improved antibiofilm properties of NP-based 
essential oil capsules. Synergistic effect was observed on early biofilms in longer co-incubation 
time course. The impact of these capsules on mature biofilms, however, needed to be evaluated as 
well. For this purpose, three day-old E. coli and P. aeruginosa biofilms were cultured and treated 
with capsules and control groups for one day. 
Figure 8.4 showed that peppermint oil completely failed to affect biofilm viability at the 
highest concentration tested, at which worked well on one day-old E. coli and P. aeruginosa 
biofilms for three hour treatment time. SiO2 NP remained unharmful for both three day-old E. 
coli and P. aeruginosa biofilms. Both P-Cap and C-Cap were effective after one day co-
incubation time and C-Cap was capable of eradicating both three day-old E. coli and P. 
aeruginosa biofilms. 
 
Figure 8.4. Viability of a. three day-old E. coli biofilms and b. three day-old P. aeruginosa 
biofilms after one day treatment with different concentrations of capsules containing peppermint 
oil and cinnamaldehyde (C-Cap, black), capsules containing only peppermint oil (P-Cap, red), 
SiO2 NP (green), and peppermint oil (Ppmt Oil, blue). Data are average of triplicates and error 
bars are standard deviation. 
The treatment of biofilms with these capsules, especially the hybrid C-Cap capsule 
showed promising antibiofilm results. The low cost of all materials including SiO2 NP and 
essential oils and the simple fabrication process made this system a great candidate for topical 
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treatment of chronic wounds. Therefore, we next employed an in vitro wound model, which was 
composed of fibroblast cells and co-cultured biofilms. This co-culture model study was 
conducted to probe the efficiency of these capsules to eradicate biofilms in the presence of 
mammalian cells as well as the toxicity of these capsules to mammalian cells. 
E. coli biofilms in co-culture model was allowed to grow on a confluent monolayer of 
3T3 fibroblast cells overnight. These co-cultures were then washed and treated with capsules as 
well as control groups for three hours. The viability of E. coli biofilm and 3T3 cells were 
evaluated respectively in each experimental group. And biofilm viability was measured by 
counting viable colonies after treatment. In the presence of bacteria and bacterial biofilms over 
night, 3T3 cells monolayer was observed to have some extension of damage. A few cells floated 
and died and they were washed away before treatment. Mammalian cell viability assessment was 
thus based on this point as starting point. And the toxicity evaluation was defined as additional 
damage caused to the remaining fibroblast cells by addition of capsules or control components.   
As shown in Figure 8.5, the hybrid capsule, C-Cap, was able to reduce log viable 
colonies in E. coli biofilms from 7 to 2 at 100% concentration. Considering log10cfu of 2 is the 
limit of sensitivity, we can assume biofilms were completely eradicated in the co-culture. 
Remarkably, C-Cap did not decrease fibroblast cell viability in the co-culture at the same 
concentration. This result demonstrated that C-Cap was able to remove biofilms in the co-culture 
model without damaging mammalian cells. P-Cap also showed removal of the E. coli biofilms in 
the co-culture model with slight toxicity at 100% concentration. SiO2 NP did not affect E. coli 
biofilms or fibroblast cells as expected. Peppermint oil was capable of reducing viable colonies in 
the E. coli biofilm by log10cfu of 1 at the highest concentration; however, 3T3 cell viability was 
also reduced to 20% by peppermint oil. 
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Figure 8.5. Viability of 3T3 fibroblast cell and E. coli biofilms in the co-culture model after three 
hour treatment with a. C-Cap, b. P-Cap, c. SiO2 NP, and d. Peppermint oil. The left y axis 
represents the viability of 3T3 cells (blue histogram) and data are average of triplicates and error 
bars are standard deviation. The right y axis represents the log10cfu of viable colonies in E. coli 
biofilms and data are average of duplicates and error bars are standard deviation. 
Encapsulation of essential oils can increase their stability and solubility, extending their 
antimicrobial application. Results in our study suggested that in addition to increased solubility, 
there may be other action pathways to increase capsule antibiofilm effect, as capsules containing 
the same amount of essential oil possessed higher killing effect. We hypothesized that the capsule 
shell formed by the amine-functionalized SiO2 NP was cationic as well, which may interact with 
biofilms, stick with biofilm anionic matrix, and release and facility cargo penetration into 
biofilms, increasing the antibiofilm property. To test this hypothesis, confocal laser scanning 
microscopy (CLSM) was employed to track capsule distribution into biofilms. SiO2 NPs used for 
capsulation were labeled with fluorescein isothiocyanate (FITC), a green fluorescent chemical, 
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and E. coli biofilms were culture with a far-red fluorescent protein, crimson, expressing E. coli. 
The 3D projection of CLSM stack images showed that when incubated with capsules, both C-Cap 
and P-Cap, FITC-SiO2 NP distributed through and all over E. coli biofilm and penetrate to the 
biofilm bottom (Figure 8.6 a, b). In the case of C-Cap, biofilm was partially eradicated and 
exhibited islands instead of layers.  SiO2 NP alone also penetrated into biofilm but in very limited 
quantity. These CLSM images demonstrated that capsules could stick on top of biofilms and 
facility cargo penetration into biofilms to escalate killing efficiency. 
 
 
Figure 8.6. Representative three dimensional projections of confocal laser scanning microscopic 
z-stack images of E. coli biofilms (red) after incubation with a. C-Cap, b. P-Cap, and c. SiO2 NP 
alone. The left panels show the green fluorescence from FITC-labeled-SiO2 NP. The middle 
panels show the red fluorescence from crimson-expressing E. coli biofilm. The right panels show 
overlay of the corresponding left and middle panel images. The z-stack images were taken at a 
o.4 µm intervals. The scale bar is 20 µm. 
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8.3 Conclusions 
In this chapter, I demonstrated the nanoparticle application for treatment of biofilms in 
the extension of nanoparticle-based capsules. SiO2 NP-based essential oil capsules showed 
improved biofilm killing effect compared to essential oil alone. The combination of 
cinnamaldehyde and peppermint oil not only improved capsule stability by cross-linking amine 
functionalized SiO2 NP, but also promoted antibiofilm efficiency. The hybrid capsule containing 
both cinnamaldehyde and peppermint oil was able to eradicate one day-old and three day-old E. 
coli and P. aeruginosa biofilms. Moreover, this hybrid capsule managed to eliminate E. coli 
biofilms formed on an in vitro wound model without causing harm to fibroblast cells underneath 
biofilms. The longer term studies, in which essential oil lost its antibiofilm effect completely 
whereas capsules preserved their killing capability, revealed the importance of using capsules 
instead of essential oils alone. This approach showed promising antibiofilm effect for application 
of treatment of biofilms as a topic emulsion agent.  
8.4 Experimental methods 
Biofilm formation in 96-well microplate Bacteria were inoculated in LB broth at 37 °C 
until stationary phase. The cultures were then harvested by centrifugation and washed with 0.85% 
sodium chloride solution for three times. Concentrations of re-suspended bacterial solution were 
determined by optical density measured at 600 nm. LB was supplemented with 0.1% glucose, 1 
mM MgSO4, 0.15 M ammonium sulphate, and 34 mM citrate and buffered to pH 7 to ensure 
bacterial adherence to the microplate. Seeding solutions were then made in this modified LB to 
reach OD600 of 0.1. 100 μL of the seeding solutions were added to each well of the microplate. 
Modified LB medium without bacteria was used as negative control. The plates were covered and 
incubated at room temperature under static conditions for three days. Fresh media was added on 
Day 2. Planktonic bacteria were removed before treatment by washing with PB saline three times.  
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Treatment of biofilms in 96-well plate Capsules were freshly made before use and a 2% 
stock solution was made in LB medium for all experiments in treatment of biofilms in 96-well 
plate. Solutions containing different capsule concentrations were made from the 2% stock 
solution. SiO2 NPs alone and peppermint oil only were used as control, and these control 
solutions were made to contain the same amount of SiO2 NP or peppermint oil as the capsule 
solutions at corresponding capsule solutions. One day-old or three day-old biofilms were washed 
with PBS for three times before treatment. 100 µL of treating solutions were then added and the 
plates were kept at room temperature for desired time course. After incubation, biofilms were 
washed again with PBS for three times, followed by addition of 100 µL of alamar blue solution. 
The plates containing alamar blue solutions were then kept at 37 °C for two hours and viability 
was measure by a plate reader at 545 nm/590 nm (Ex/Em). 
Biofilm-3T3 fibroblast cell co-culture 20,000 NIH 3T3 (ATCC CRL-1658) cells were 
cultured in Dulbecco's modified Eagle medium (DMEM; ATCC 30-2002) with 10% bovine calf 
serum and 1% antibiotics at 37 °C in a humidified atmosphere of 5% CO2. Cells were kept for 48 
hours to reach a confluent monolayer. Bacteria were inoculated and harvested as described above 
and seeding solutions were made in HEPEs buffered DMEM with 2% glucose and 10% bovine 
calf serum to reach OD600 of 0.1. The buffered medium was used to maintain pH during 
incubation without CO2. And the supplemented glucose was used to maintain bacteria and 
bacterial biofilm growth. No antibiotics were added. Old medium was removed from 3T3 cells 
followed by addition of 100 μL seeding solution. The co-cultures were then stored in a box with 
damp paper towels at 37 °C overnight. The co-cultures were washed with PB saline three times 
before treatment to remove planktonic bacteria and non-adherent 3T3 cells. 
Treatment of biofilms in co-cultures Capsules were freshly made before use and a 2% 
stock solution was made in warm HEPEs buffered DMEM for all experiments in treatment of 
biofilms in co-cultures. Solutions containing different capsule concentrations were made from the 
2% stock solution. SiO2 NPs alone and peppermint oil only were used as control, and these 
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control solutions were made to contain the same amount of SiO2 NP or peppermint oil as the 
capsule solutions at corresponding capsule solutions. Co-cultures were washed with PBS for three 
times before treatment. 100 µL of treating solutions were then added and the plates were kept at 
37 °C for three hours.  
To evaluate 3T3 fibroblast cell viability, LDH (lactose dehydrogenase) cytotoxicity assay 
was used. For negative controls (spontaneous LDH activity controls), medium of one set of 
triplicate wells was removed, and 100 μL of fresh warm DMEM and 10 μL of sterile MQ H2O 
was added. For positive controls (maximum LDH activity controls), medium of another set of 
triplicate wells was removed, and 100 μL of fresh warm DMEM and 10 μL of Lysis Buffer (10X, 
from the LDH kit) was added. After incubation, 50 μL of each sample medium (e.g., experiment 
wells, spontaneous LDH activity controls, and maximum LDH activity controls) was transferred 
to a clear 96-well plate, and 50 µL of reaction mixture was added to each sample well. The plate 
was then incubated at dark at room temperature for 30 minutes, followed by addition of 50 µL of 
stopping solution to each well and mixed by gentle tapping. The absorbance was then measure by 
a plate reader at 490 nm and 680 nm. The LDH activity was calculated by subtracting the 680 nm 
absorbance value from the 490 nm absorbance value. %Cytotoxicity = (Compound-treated LDH 
activity – Spontaneous LDH activity)/(Maximum LDH activity – Spontaneous LDH activity) × 
100. 3T3 fibroblast cell viability was then calculated by subtracting %Cytotoxicity from 100%. 
To evaluate biofilm viability, co-cultures were washed with PBS once after the three hour 
incubation time. 200 µL of sterile PBS was then added into each well and the plate was sealed 
with parafilm and sonicated for 20 minutes. After sonication, plate was carefully wiped dry. Each 
well was then scratched with a clean sterile pipette tip and mix well. Series dilution was done and 
10 μL of dilution of interest were placed on LB agar. Agar plates were kept at 37 °C over night 
and colonies were counted. Biofilm colonies were defined as Colonies/10 μL × Dilution times × 
200 μL, and log reduction = Log10 (Untreated biofilm colonies) – Log10 (Treated biofilm 
colonies). 
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Biofilm culture for CLSM Bacteria were inoculated in 3 mL LB broth and grown to 
stationary phase at 37 °C. The cultures were then diluted 1:100 in a 1/10 strength LB broth 
supplemented with 100 μM IPTG (isopropyl β-D-1-thiogalactopyranoside). 25 mL of the dilution 
was transferred into a petri dish containing six sterile glass cover slips (22 × 22 mm). The petri 
dish was kept at 25 °C and the biofilms were allowed to grow for three days. In general, the cover 
slips with biofilms were rinsed in deionized water for three times before placed in capsule 
solutions. The biofilms were incubated in 100% capsule solutions for one hour and free capsules 
were washed away by rinsing in deionized water for three times. 
CLSM image The CLSM images were obtained using Zeiss510 META. The green 
fluorescent channel was collected at 488/505-550 bad pass and the red fluorescent channel was 
collected at 543/560 longpass. 
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